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DEDICATION
To whomever has a dream or goal in life. If you believe it, you can achieve it. I
recall during my 1st year as a doctoral candidate I came across a PhD candidate’s
memoir about his experience from Massachusetts Institute of Technology (MIT).
What this student had written in his memoir but particularly in his epilogue had an
everlasting impression on me and was one of many sources of motivation through
the ups & downs of graduate school. “So why would anyone spend six or more
years doing a PhD when they aren't going to become professors? Everyone has
different motivations but one possible answer is that a PhD program provides a
safe environment for types of people to push themselves far beyond their mental
limits and then emerge stronger as a result. For example, my six years of PhD
training have made me wiser, savvier, grittier and more steely, focused, creative,
eloquent, perceptive, and professionally effective than I was as a fresh college
graduate.” – Philip J. Guo
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ABSTRACT OF DISSERTATION
ID3, ESTROGENIC CHEMICALS, AND THE PATHOGENESIS OF TUMOR LIKE PROLIFERATIVE VASCULAR LESIONS

Vincent E. Avecilla
Florida International University, 2017
Miami, Florida
Professor Quentin Felty, Major Professor
Tumor-like proliferative vascular lesions manifest in several diseases such as
peripheral arterial disease (PAD) and atherosclerosis (AS) after arterial injury. The
cause of the vascular cell dysfunction in PAD patients is not known. Our recent
novel discovery shows that inhibitor of differentiation 3 (ID3) is highly expressed in
intimal lesions of clinical vascular disease samples. The central hypothesis of our
study is: estrogenic chemical induced dysregulation of ID3 target genes is involved
in the development of vascular disease. NHANES data analysis demonstrated
higher geometric levels of all 6 PCB congeners in both PAD diagnosed participants
and defined AS participants when compared to the rest of the population. Adjusted
models showed association between higher exposure of PCBs, phthalates, BPA,
and increased risk of PAD. Furthermore PCB153 was shown to have the highest
geometric mean amongst all PCB congeners in both participants diagnosed with
PAD and at risk of AS. Gene expression of ID3 & ID3 candidate targets in blood &
tissue studies identified ID3 & ID3 candidate target genes as a driver of vascular
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disease. Overlapping ID3 & ID3 candidate target genes included: ABCB6, ACP1,
BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, ID3, MCM4, and NDUFA7. The
ID3 target genes involved in the: focal adhesion pathway were ACTN1, COL1A2,
COL3A1, COL6A1, CTNNB1, IBSP, ID3, ITGA8, and MYL2; ECM-receptor
interaction were COL1A2, COL3A1, COL6A1, IBSP, ID3, and ITGA8; oxidative
phosphorylation pathway ATP5D, ATP5H, ATP6V0B, ATP6V0D1, ATP6V1B2,
COX5A, COX7C, COX8A, CYC1, ID3, NDUFA1, NDUFA7, NDUFS4, NDUFV1,
NDUFV2; and cell cycle pathway ANAPC10, ATM, CDKN2B, E2F5, MCM3, and
MCM4. In summary our results showed an association between exposure to PCBs,
phthalates, BPA, and increased risk of PAD and AS, and possible molecular
mechanisms of interaction of ID3 target genes and estrogenic chemicals involved
in PAD and AS.
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CHAPTER I
INTRODUCTION
Systematic & pulmonary vascular biologists have inclined to position their
particular research in different ways. This distinction is readily implicit in light of
their predominantly different interests. Those that are engaged in research on
pulmonary circulation have often centered their attention on pulmonary arterial
hypertension, a life threatening condition that affect your arteries which go from
your heart to your lungs. Oppositely systematic circulation have traditionally
focused on the pathogenesis of atherosclerosis, a common disease that affects
large arteries and in which the lipid metabolism features chiefly have been
explored in mechanisms in restenosis after angioplasty. These divergent pathways
intersect at obliterative and proliferative vascular diseases which commonly disrupt
the blood vessel. These two types of vascular diseases certainly have similar
elements such as interactions between the vessel wall and various components of
blood. Others involve interactions between the smooth muscle of the media &
endothelial lining but while exasperating and preserving mechanisms have been
established in both, the unique perturbations that initiates these processes remains
uncertain.
A class of proteins that have been seen to be involved with these types of
vascular diseases are ID proteins (ID1, ID2, ID3, and ID4). Their names relate to
their ability to regulate the programming of cell fate determination and
differentiation in various types of cells through normal development and adult life
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(Lasorella et al., 2014). The ID3 gene was first identified as a serum-inducible
immediate early gene in an established murine fibroblastic cell line (Christy et al.,
1991). Previous studies have demonstrated its involvement in various biological
processes, including: tumor-induced angiogenesis, embryonic neurogenesis,
osteogenesis, vascular smooth muscle cell proliferation, T & B cell development,
and skeletal muscle differentiation (Atherton et al., 1996; Deed et al., 1996;
Melnikova & Christy, 1996; Pan et al., 1999, Lyden et al., 1999; Rivera et al., 2000;
Forrest et al., 2004; Maeda et al., 2004). ID3 has been shown to be involved in
various types of vascular diseases such as adult kidney injury (AKI) which is
involved in loss of capillary function and vascular remodeling in the luteum (CL), a
temporary endocrine organ that is involved in the production of high levels of
progesterone and moderate levels of estradiol, atherosclerotic disease, and
pulmonary hypertension (Lee et al., 2014; Yang et al., 2013; Nio-Kobayashi et al.,
2012; Doran et al., 2010). Expression and function of the protein is under several
multifaceted layers of regulation and therefore can provide beneficial targets for
therapeutic interventions.
Vascular diseases can manifest from a combination of both environmental
& molecular determinants. Progression in machine/deep learning and genomic
technologies have facilitated investigators to generate hypotheses regarding the
integration & contribution of genetic factors at a rapid pace. However, the
assessment of specific and numerous environmental pollutants and their
interactions with the genome has not. There still lacks methodologies to
comprehensively analyze and interpret several multifaceted environmental &
2

cellular constitutes to disease and human health. One environmental determinant
that has been demonstrated to show association with ID3 are chemicals commonly
known as estrogenic or endocrine disrupting chemicals (EDCs). These chemicals
are synthetic and natural that have the ability to disrupt metabolic pathways by
either mimicking or blocking endogenous hormones and modifying hormone
function (Roy et al. 1997). Many EDCs are considered highly carcinogenic and
include an assortment of chemicals such as industrial compounds, by-products of
industrial procedures, chemicals that are used in the manufacturing of plastics, and
pesticides. Of specific concern to public health professionals are agents that are
persistent in the environment that are hormonally active, greatly lipophilic, amplify
within the food chain, and are readily bio-accumulative (Lyche et al., 2009; Meeker
et al., 2009).
Since many of these chemicals are used in numerous amounts of consumer
products, exposure to EDCs through the general population is prevalent. Human
exposure to EDCs may result in different ways such as absorption through the
skin, ingestion of contaminated food & water, and airborne inhalation (Balabanic
et al., 2001). During the last decade multiple EDC exposure such as
polychlorinated biphenyls (PCBs), bisphenol A (BPA), and phthalates have been
detected in > 90% urine & blood samples collected from the general population of
the United States (Silva et al., 2004; Calafat et al., 2008; Woodruff et al., 2011).
EDCs that are persistent today in the environment have shown properties of
endocrine disruption. PCBs have demonstrated to have estrogenic and antiestrogenic properties contingent on the congener. Previously PCB exposure has
3

been shown to be associated with cardiovascular disease (Perkins et al. 2016).
Higher exposure of urinary phthalates furthermore have been demonstrated to be
associated with hypertension in childhood (Trasande et al. 2013). Exposure to BPA
has demonstrated to result in atherosclerosis, altered cardiac remodeling, and
changes in blood pressure in rodents (Gao & Wang, 2014). Although there are
vast amount of EDCs in the environment the most extensively studied EDCs
include polychlorinated biphenyls, phthalates, and bisphenol A.
The existing disciplines of studying environmental pollutants & molecular
determinants of health include epidemiology, molecular/genetic biology, &
toxicology which function on population, bioinformatics, and molecular scales,
respectively. This dissertation proposes methodology in all of these disciplines
emphasizing the framework of environmental - and genomic - wide association
studies through the utilization of public databases such as the National Health and
Nutrition Examination Survey (NHANES) and NCBI Gene Omnibus Expression
(GEO). The overachieving goals of this research was to first determine the
association between exposure to these endocrine disrupting chemicals in a U.S.
population diagnosed with vascular disease and secondly; determine the role of
ID3 in vascular-intimal lesion formation and investigate its activity via regulation of
cell adhesion, extracellular matrix proteolysis, and cell growth. Documenting both
exposure to EDCs among the U.S. population & associations with vascular disease
and the role of ID3 in vascular-intimal lesions will help guide our understanding of
the complexity of environmental molecular determinants in vascular disease.
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HYPOTHESIS
Estrogenic chemical induced dysregulation of ID3 target genes is involved in the
development of vascular disease
SPECIFIC AIMS
Aim 1: Collect environmental exposure data from National Health and Nutrition
Examination Survey (NHANES) database and gene expression data from the
Gene Expression Omnibus (GEO) database
Aim 2: Investigate the association between exposure to estrogenic chemicals and
vascular disease (peripheral arterial disease)
Aim 3: Identify ID3 regulated molecular gene networks
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CHAPTER II
REVIEW OF LITERATURE
MANUSCRIPT 1
Contribution of Inhibitor of DNA-binding/Differenatiation-3 (ID3) and endocrine
disrupting chemicals to pathophysiological aspects of chronic disease
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Abstract
The overwhelming increase in the global incidence of obesity and its associated
complications such as insulin resistance, atherosclerosis, pulmonary disease, and
degenerative disorders including dementia constitutes a serious public health
problem. The Inhibitor of DNA binding/Differentiation-3 (ID3), a member of the ID
family of transcriptional regulators, has been shown to play a role in adipogensis
and therefore ID3 may influence obesity and metabolic health in response to
environmental factors. This review will highlight the current understanding of how
ID3 may contribute to complex chronic diseases via metabolic perturbations.
Based on the increasing number of reports that suggest chronic exposure to and
accumulation of endocrine disrupting chemicals (EDCs) within the human body are
associated with metabolic disorders, we will also consider the impact of these
chemicals on ID3. Improved understanding of the ID3 pathways by which exposure
to EDCs can potentiate complex chronic diseases in populations with metabolic
disorders (obesity, metabolic syndrome, and glucose intolerance) will likely provide
useful knowledge in the prevention and control of complex chronic diseases
associated with exposure to environmental pollutants.

Keywords: endocrine disrupting chemicals, ID3, metabolic disorders, chronic
disease
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Introduction
Inhibitor of DNA binding/Differentiation-3 is a member of the ID family of helix-loophelix proteins encoded by an immediate-early gene responsive to mitogenic
signals and oxidative stress. ID3 functions as a transcriptional regulator known to
prevent stem cell differentiation and promote cell cycle progression. An increasing
body of evidence suggests that ID3 may be involved in metabolic perturbations
characterized

by

insulin

resistance,

hyperglycemia,

abdominal

obesity,

dyslipidemia, and hypertension. Interactions across multiple organ systems that
contribute to metabolic perturbations presents a challenge to ongoing research
attempting to elucidate biological mechanisms of chronic disease associated with
metabolic health. For instance, insulin resistance and systemic low-grade
inflammation result from complex interactions between the vasculature, metabolic
tissue, and immune cells. With regard to these interactions, it is noteworthy that
ID3 plays a significant role in vasculogenesis, energy metabolism, and in the
development of the immune system. In the vasculature, ID3 is essential to
embryonic vasculogenesis and endothelial cell activation (Sakurai et al. 2004;
Felty and Porther. 2008; Eelen et al. 2015). Given that metabolic perturbations are
observed in endothelial cells from diseased vasculature (He et al. 2014), ID3 may
mediate endothelial dysfunction often found in individuals with metabolic
syndrome. In addition to the vasculature, ID3 function spans to metabolic tissue
and immune cells. In vivo studies have demonstrated that ID3 mediates high fat
diet induced obesity and promotes obesity-induced inflammatory macrophage
accumulation (Doran et al. 2008; Cutchins et al. 2012). Thus, we intend to discuss
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the current understanding of how ID3 may influence chronic diseases associated
with metabolic perturbations. Since adipose tissue is an endocrine organ as well
as a metabolic organ, exposure to endocrine disrupting chemicals (EDCs) may
also contribute to metabolic perturbations associated with chronic disease. EDCs
are mostly synthetic chemicals ubiquitously found in our environment that act by
altering hormone action. Estrogenic EDCs such as diethylstilbestrol (DES),
bisphenol A (BPA), estrogenic polychlorinated biphenyls (PCBs), and phthalates
have been implicated to interfere with metabolic health during critical periods of
development and into adulthood. Epidemiological studies have reported
associations between exposures to EDCs and metabolic syndrome (Swedenborg
et al. 2003; Hatch et al. 2010; Casals-Casas and Desvergne. 2011). Based on our
recent findings that showed ID3 dependent endothelial cell activation by exposure
to estrogenic PCB congener 153 (Felty. 2011; Das and Felty. 2014), we will also
discuss how low dose EDC exposure from the environment may potentiate
complex chronic disease in populations with metabolic disorders (obesity,
metabolic syndrome, and glucose intolerance) via ID3. A better understanding of
interactions between ID3 and EDC is critical in deepening our understanding of
how environmental factors modify chronic disease risk and health outcomes.
Further study in these areas may reveal novel or more effective therapeutic
modalities as well as provide prevention and control strategies of complex chronic
diseases associated with exposure to EDCs.
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Inhibitor of DNA binding/Differentiation-3 (ID3)
Structure and Function. The ID (Inhibitor of DNA binding/Differentiation) family
of small proteins consists of four genes (ID1-ID4). The four members of the ID
family share extensive amino acid sequence homology (69-78%) within their helixloop-helix (HLH) domain (Lyden et al. 1999, Yang et al. 2014), but the remaining
parts of the proteins are non-related. Experimental studies in genetically
engineered mice have revealed the importance of ID3 in embryonic development
and cell differentiation. ID3 gene knockout mice are viable, however, they have
demonstrated defects in immune cell differentiation (Pan et al. 1999; Lasorella et
al. 2014). In contrast, double ID1/ID3 knockout mice showed abnormal
vascularization of the brain (Poulsen et al. 2001), neuronal differentiation, and
cardiac defects (Fraidenraich et al. 2004) that were embryonically lethal.
Resistance to tumor angiogenesis was reported in mice deficient in 1-3 alleles of
ID1/ID3 gene knockout combination (Lyden et al. 1999). ID3 is highly expressed
in embryonic tissue, but declines as cells differentiate (Lyden et al. 1999). In adult
tissues, the expression of ID3 is context specific and tends to be highest in
proliferating and undifferentiated cells. ID3 expression has been reported to be
induced by diverse stimuli in many cell types (Lim and Wu. 2005).
The ID3 gene was initially identified as a serum-inducible immediate-early
gene in mouse fibroblasts that peaks transcriptionally at 1h (Lasorella et al. 2001;
Lasorella et al. 2014). Subsequently, ID3 expression has been reported to be
biphasic with maximal stimulation at 1h following a second burst at 24h as in the
case of tissue regeneration after injury. We and others have shown that ID3
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expression is redox sensitive (Felty and Porther. 2008; Mueller et al. 2012)
specifically, we have shown that vascular endothelial cells exposed to either 17βestradiol (E2) or the estrogenic PCB congener 153 (PCB153) resulted in increased
ID3 expression, protein phosphorylation, and endothelial neovascularization.
Treatment with reactive oxygen species scavengers inhibited estrogenic chemical
induced neovascularization (Das and Felty. 2014; Das and Felty. 2014).
Proteasomes reportedly degrade ID3 by an ubiquitin dependent mechanism. The
protein half-life of ID3 has been demonstrated to be approximately 20 min in
HEK293 cells (Yang and Morrell. 2014). In mammals, ID protein-protein
interactions occur via the HLH-motif in which ID proteins dimerize and block the
DNA binding activity of basic HLH transcription factors, such as a group of E
proteins (E12/E47, E2-2, HEB) encoded by the TCF3, TCF4, and TCF12 gene,
respectively. Among these E proteins, ID3 has been most often reported to interact
with E12/E47 (Loveys et al. 1996). The E proteins are basic HLH transcription
factors that bind to the E-box consensus sequence (CANNTG) in the promoter of
target genes. ID3 plays an important role in cell proliferation via its interactions with
E proteins. For example, E proteins have been shown to bind the E-box sequence
in the promoter of the cyclin dependent kinase inhibitor p21 Cip1 and activate its
transcription (Liu et al. 2004). The level of p21Cip1 is elevated in quiescent cells
where it acts as a suppressor of cell proliferation (Sherr and Roberts. 1995). In the
context of the cell cycle, ID3 promotes cell cycle progression by the inhibition of
p21Cip1 expression (Forrest and McNamara. 2004). Specifically, ID3 protein-protein
interactions with E proteins can disrupt their ability to bind gene promoters and
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thereby blocks transcriptional activation by these factors. ID3 has been shown to
inhibit E proteins from activating the p21Cip1 promoter in proliferating vascular cells
(Taylor et al. 2006). Thus, ID3 has been frequently described as a dominant
negative inhibitor of E proteins. Although ID proteins have been shown to function
as dominant negative transcriptional regulators of E proteins, there may be
circumstances by which ID3 acts as a positive transcriptional regulator. ID3 has
been shown to regulate the binding of Transcription Factor 3 (TCF3) to the E-box
motif in target gene promoters (Langlands et al. 1997). TCF3 has been reported
to repress the expression of pluripotency genes OCT4, SOX2, and NANOG that
contribute to cell differentiation (Lasorella et al. 2014). Our research has shown
that ectopic overexpression of ID3 increased OCT4 and SOX2 expression in
endothelial cells as well as resulted in a population of cells that were positive for
the molecular stemness signature CD133+ VEGFR3+ CD34+ (Felty et al. 2015).
These endothelial stem cells were morphologically differentiated into smooth
muscle cells and neuron cells. Based on these lines of evidence, ID3 maintains
cells in an undifferentiated or non-committed state by preventing the repression of
pluripotency factors by TCF3. Hence, it is also plausible for ID3 to function as a
positive regulator of gene transcription. In lieu of a recent report that showed ID3
to modulate genes essential for maintaining genome integrity during cell division
(Ji et al. 2011) a dual regulatory role of ID3 in both positive and negative gene
transcription expands its influence as shown in Figure 1.1. ID3 protein-protein
interactions are not exclusive to E-proteins as ID proteins have also been reported
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to bind to proteins that do not contain the HLH motif such as caveolin-1 (Zhang et
al. 2007).

Figure 1.1 ID3 transcriptional regulation. Scheme illustrating how ID3 can repress expression of p21 gene
(upper panel) or activate gene expression of embryonic transcription factors (lower panel).

ID3 and Metabolic Syndrome (MetS)
There has been increasing evidence that ID3 plays a role in adipogenesis.
ID3 through adiponectin is considered to improve β-cell function, circulating lipids,
and insulin sensitivity levels (Arita et al.1999; Steinberg and Kemp. 2009). ID3
inhibits transcriptional activity of E47 in undifferentiated pre-adipocytes (Doran et
al. 2008). ID3 negatively inhibits the FAS (fatty acid synthase) promoter via SREP1c in adipose tissue. ID3 furthermore plays a role in blood glucose, which if
dysregulated can lead to insulin resistance. In human islet cells ID1 and ID3 mRNA
levels are increased with addition of glucose (Wice et al. 2001). The induction of
ID1 and ID3 expression, insulin secretion, and gene transcription suggests that
IDs may play a role in promoting β-cell function (Wice et al. 2001, Lee et al. 2011).
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ID3 & Endocrine Disrupting Chemicals Influence Metabolic Perturbation
Metabolic Syndrome (MetS) and its associated complications such as
insulin resistance, abdominal obesity, dyslipidemia, and hypertension contribute to
chronic diseases including cardiovascular disease (CVD), type 2 diabetes, cancer,
and chronic kidney disease (CKD). Some studies have shown the prevalence of
MetS in the United States at approximately 34% of the adult population (Ford et al.
2002). MetS is an illness of energy consumption and storage which is a diagnosis
of the co-occurrence of a minimum of three of the following medical conditions:
abdominal obesity, high triglyceride levels, low HDL cholesterol levels, high fasting
blood sugar, and high blood pressure. The molecular mechanisms of MetS are not
fully understood. Most patients are older, sedentary, obese, and have a certain
amount of insulin resistance. Important factors that are associated with MetS can
include aging, diet, sedentary behavior, genetics, excessive alcohol use, or low
physical activity (Poulsen et al. 2001; Pollex and Hegele. 2006; Malik et al. 2010;
Edwardson et al. 2012). MetS appears to have three conceivable etiological
groupings: obesity and disorders of adipose tissue; insulin resistance; and a
collection of independent factors (ex: molecules of hepatic, vascular, and
immunologic origin).
Inflammatory factors produced during obesity are a major pathway for
developing metabolic perturbation which can lead to MetS. Experimental studies
have demonstrated ID3 to be a key regulator of Monocyte chemoattractant protein1 (MCP-1) (Kapla et al. 2015). MCP-1 is a well-known chemokine impacted by
MetS (Panee. 2012). ID3 has also been reported to regulate the production
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of interleukins IL-5, IL-6, IL-8, and IL-10 (Jin et al. 2011; Kuo et al. 2011; Perry et
al. 2012).The induction of these chemokines have been observed in population
studies of obesity and/or MetS. ID3 is also an oxidative stress regulated gene
which may provide a positive feedback pathway in response to metabolic
perturbations (Mueller et al. 2002; Felty and Porther. 2008). Taken together, these
lines of evidence provide the basis for how ID3 can participate in metabolic
perturbations via controlling the expression of inflammatory factors involved in
obesity and/or MetS. A growing number of reports implicate endocrine-disrupting
chemicals (EDCs) as an environmental factor that contributes to the occurrence of
MetS. We performed a comprehensive search in the Comparative Toxicogenomic
Database (CTD) to identify known ID3 and EDC interactions with results shown in
Table 1 (Mattingly et al. 2004).
Table 1. ID3 and Endocrine Disrupting Chemicals (EDCs)
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Table 1. ID3 and Endocrine Disrupting Chemicals (EDCs). ID3 and endocrine disrupting chemical
interaction created via Comparative Toxicogenomic Database (CTD).

Adipose tissue is highly connected to steroid hormones (estrogens,
androgens, and glucocorticoids) and maintains a close relationship with the
immune system via adipokines. Endocrine disruption can interfere with the
creation, discharge, breakdown, elimination, and imitation of natural hormones (Jin
et al. 2013). EDCs can be cataloged into multiple groupings such as dioxins,
organotins, plastics, and pesticides. The increased presence of EDCs in the
environment may help explain the incidence of metabolic disorders and associated
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complications. EDCs are found in everyday products (including food, plastic
bottles, metal cans, toys, cosmetics, & pesticides) and used in the manufacture of
food. Exposure to EDCs may regulate inflammatory factors via ID3. TCDD and
PCB congeners have been shown to up-regulate MCP-1 expression (Kirkley and
Sargis. 2014). Bisphenol A exposure has been reported to increase IL-6 (Aremma
et al. 2016). Population studies furthermore have reported an association between
bisphenol-A plasma levels and pro-inflammatory cytokines including IL-6
(Savastano et al. 2015). Besides inflammation, ID3 may contribute to other risk
factors of MetS such as angiogenesis, adipose tissue, blood glucose levels, and
insulin resistance. PCBs have been associated with MetS in epidemiological
studies (Uemura et al. 2009). In the mouse model, PCB153 has been shown to
produce significant metabolic changes when administered with a high fat diet that
were consistent with worsened obesity and nonalcoholic fatty liver disease
pathology (Wahlang et al. 2013). ID3 may contribute to MetS via visceral fat
expansion that was demonstrated in mice fed a high-fat diet (Cutchins et al. 2012).
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ID3 deficiency resulted in greater energy expenditure and higher metabolic rate in
mice at rest. With respect to metabolic disorders involving high glucose levels; ID3
may be impacted because it was shown to be regulated by glucose in pancreatic
islet β-cells (Wice and Permutt. 2001) and under chronic hyperglycemic conditions.
ID family proteins were stabilized by which in turn activated metabolic genes
(Gronning et al. 2006). Since a causal link of diabetes and vascular disease is
chronic hyperglycemia, ID3 may also contribute to metabolic perturbations from
high blood glucose levels. More importantly, however, is that mitochondrial
reactive oxygen species (ROS) produced by vascular endothelial cells under
hyperglycemic conditions may share a pathway similar to environmental toxicant
induced oxidative stress which converges on ID3. PCBs have been reported to
have estrogenic activity (Bitman and Cecil. 1970; Meek and Finch. 1999; Tavolari
et al. 2006; Davey et al. 2007). PCB153 is an agonist for the pregnane X receptor
(PXR) and the constitutive androstane receptor (CAR) which exert their effects on
energy metabolism through gene regulation (Wada et al. 2009). Hence,
dysregulation of these receptors by EDCs may contribute to PCB-induced
metabolic perturbations. Several epidemiological studies have reported the
association of PCB exposure with the increased risk of cardiovascular disease
(Hay and Tarrel. 1997; Gustavsson and Hogstedt. 1997; Tokunaga and Kataoka.
2003; Sergeev and Carpenter. 2005; Goncharov et al. 2011). Since cardiovascular
disease is a chronic disease affected by metabolic perturbations, we investigated
the effects of PCB153 exposure on ID3 in vascular cells. Based on known PCB
blood levels from occupational exposure, we showed a significant increase in
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PCB153-induced vascularization at doses of 10-100 ng/ml which was ID3
dependent (Felty. 2011). We have shown that PCB-induced ROS mediated a
highly branched neo-vascular phenotype depended on ID3 and Pyk2 (Das and
Felty. 2014). Because the level of ID3 protein is determined by the rates of protein
synthesis and protein degradation, we tested if PCB153 treatment affected ID3
protein synthesis. We showed that estrogenic chemical induced ID3 did not
depend on protein synthesis, instead PCB153 treatment increased ID3 protein
stability in endothelial cells. The role of phosphorylation in the regulation of ID3
protein stability is not known. A search with the PhosphoMotif finder program
revealed that ID3 had 38 serine kinase/phosphatase motifs and 8 tyrosine
kinase/phosphatase motifs (Amanchy et al 2007). We reported that both E2 and
PCB153 induced ID3 phosphorylation. E2 treatment stabilized ID3 protein during
the 1-6h treatment time points and increased phosphorylated ID3 levels (Das and
Felty. 2014, Das and Felty. 2014). It was noteworthy that we showed data of ID3
tyrosine phosphorylation by PCB153 treatment which was confirmed by MALDITOF MS/MS spectra data. Our findings revealed phosphorylated amino acids Tyr11 and Tyr-48 in peptides from ID3. Interestingly, Tyr-48 is positioned in the helixloop-helix motif that is essential for protein binding. Currently, it is not clear whether
PCB153-induced phospho-ID3 leads to protein-protein interactions that may
prevent its degradation; however, our findings demonstrated that ID3 is a target of
post-translational modifications by the endocrine disruptor PCB153 in vascular
endothelial cells. Based on these lines of evidence, estrogenic chemical-induced
ID3 signaling contributes to hyperplastic vascular lesions. This vascular cell
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dysfunction may be a pathway by which EDCs and ID3 contribute to cardiovascular
disease (Felty and Porther. 2008). Based on these findings, we propose that ID3
is a target of EDCs that can activate inflammatory and energy pathways
susceptible to metabolic perturbation during chronic disease pathogenesis. In the
next section, we intend to discuss the current mechanistic understanding of how
ID3 may influence chronic diseases associated with metabolic perturbations.

ID3 & Disease Outcomes
Vascular Diseases. ID3 involvement in vascular disease has been studied
together with the lipoxygenase (12/15-LO) which is known to generate proinflammatory changes in blood vessels that precede the development of
atherosclerosis (Chakrabarti et al. 2009). 12/15-LO is an important mediator of
VSMC growth and its growth-promoting effects were shown to be mediated by ID3
transcription (Taylor et al. 2005). Increased expression of 12/15-LO in the vessel
wall enhanced ID3-dependent cell proliferation, fibronectin deposition, and
neointimal formation. Population based studies have found a SNP (single
nucleotide polymorphisms) rs11574 in the coding region of the human ID3 gene
associated with subclinical atherosclerosis in the Diabetes Heart study (Doran et
al 2010). ID3 SNP rs11574 showed a significant association of coronary artery
disease for caucasians and to a lesser extent in African Americans and Hispanics
(Manichaikul et al. 2014).
Ectopic expression of ID3 in VSMC (vascular smooth muscle cells)
regulates the cell-cycle (Yang et al. 2013). ID3 has also been shown to play a
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complex role with atherosclerosis. ID3 expression is increased by hyperlipidemia
and oxidized LDL (Taylor et al. 2006). ID3 regulates angiotensin II and carotid
intima-media thickness. Angiotensin II promotes hyperplasia through up-regulating
ID3 (Owens. 2009). The ID3 SNP could be a potential loss of function mutation if
it inhibits the functioning of E proteins, thus being an atheroprotective factor. As
shown in Figure 1.2, ID3 may impact vascular cell dysfunction leading to intimal
lesions.

Figure 1.2 ID3 molecular mechanism & vascular diseases. Summary illustration of ID3 signaling involved
in vascular disease pathogenesis. ID3 signaling can lead to neo-intimal lesions or vascular remodeling by
transcriptional regulation of the target genes described above.

ID3 stimulates visceral adipose VEGFA expression, depot expansion and
micro-vascular blood volume (Cutchins et al. 2012). ID3 promotes angiogenesis in
HFD (high-fat diet)-induced visceral adiposity (Cutchins et al. 2012). ID3 KO shows
a protective effect from HFD-induced visceral fat depot expansion. Furthermore,
HFD-induced VEGFA expression in visceral adipose tissue was completely
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abolished by loss of ID3. BMP9 induces both ID1 and ID3 which are necessary for
induction of EphrinB2 (Kim et al. 2012). A summary in Figure 1.3 shows an ID3
signaling pathway involved in vascular malformations.

Figure 1.3 ID3 involvement in arteriovenous malformation. Summary of experimental studies showing
impact of ID3 in vascular cell dysfunction.

Neurological Disorders. The ID3 gene is biologically relevant to neurological and
behavior research because of its involvement in the stress response, neural
plasticity, and neural circuitry. Molecular genetic studies in mice have shown that
ID3 is required for embryonic neurovascular development. Genetic loss of ID1 and
ID3 led to deviant neurovascular formations resulting in death (Lyden et al. 1999).
ID1 and ID3 mutants showed premature differentiation of CNS radial glial cells that
greatly increased neurons. Since radial glial cells, function as scaffolds for
developing blood vessels in the CNS, alterations to their development in ID1/ID3
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knockout mice may contribute to deviant blood vessel morphogenesis and
hemorrhage. ID1 and ID3 may function beyond maturation of the CNS
neurovasculature because other pathways such as Notch1 activation do not
support neurovascular disorders (O’Brien et al. 2012; Solozobova et al. 2012).
Psychopathologies such as anxiety and depression have been associated with ID3
methylation status. Epigenetic changes in ID3 have been associated with
maltreatment of children as well as demonstrated as a predictor for depression.
Montalvo-Ortiz et al reported epigenetic alterations in DNA derived from saliva in
three genes predicted depression in a cohort of maltreated children: ID3,
Glutamate NMDA Receptor (GRIN1), and Tubulin Polymerization Promoting
Protein (TPPP) (Montalvo-Ortiz et al. 2016). Studies of the expression of these
genes from medial prefrontal cortex (mPFC) tissue of mice subjected to a model
of maternal neglect, which comprised of maternal separation and early weaning
(MSEW). Behavioral tests were performed in MSEW and control adult male mice
by the higher plus maze (EPM) and forced swimming test (FST), respectively
(Montalvo-Ortiz et al. 2016). Behavioral differences in the EPM and FST tests
showed that these genes ID3, GRIN1 and TPPP gene could predict anxiety and
depression. Based on these studies, ID3 may contribute to the etiology of anxiety
and depressive phenotypes when exposed to early life stress (Montalvo-Ortiz et
al. 2016) (Figure 1.4).
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Figure 1.4 Epigenetic mechanism of ID3 in neurological disorders. Summary of ID3 involvement in
neurological disorders is presented.

Both environmental & genetic factors contribute to the progression of MetS
and neurodegenerative disorders (Campos-Peña et al. 2017). Numerous studies
have demonstrated that pre-diabetes and diabetes mellitus support cognitive
decline related to Alzheimer's disease (AD) and vascular dementia (Campos-Peña
et al. 2017). For example, sucrose-treated mice develop mitochondrial
abnormalities with significant increase in Aβ levels, and slight increase in pTau
levels which links metabolic perturbations from sucrose consumption with the ADlike pathology. Epigenetic changes in ID3 have been associated with maltreatment
of children as well as demonstrated as a predictor for depression (Weder et al.
2014). Another epigenetic study of individuals with Autism spectrum disorders
(ASD) revealed a significant association with a microRNA that targets ID3
(Sarachana et al. 2010). This is interesting as ID3 is also a neuronal target of
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MeCP2 which is the causative gene for Rett syndrome in which afflicted children
often exhibit autistic-like behaviors (Peddada et al. 2006). The overlap in the
clinical symptoms of ASD, ADHD, and neurodegenerative disorders raises the
question of whether epigenetic regulation of ID3 plays a role.
Population-based studies have demonstrated an association between toxic
environmental chemical exposures and impaired neurodevelopment that may
impact neurobehavioral disorders (Rossignol et al. 2014). Exposure to air
pollutants from traffic and coal emissions are well-known risk factors for both
attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders
(ASD) (Heilbrun et al. 2015). Polychlorinated biphenyls (PCBs) are endocrinedisrupting chemicals shown to adversely affect cognitive performance. Children
exposed to PCBs have shown behavioral impairments as well as significant deficits
in verbal and full-scale IQ (Chen et al. 1994). Urban areas are important regional
sources of airborne PCBs and population-scale airborne exposure. Although PCBs
have not been intentionally produced in the U.S. since the late 1970s, they
continue to be detected in ambient air samples throughout the world (NIEHS, NIH).
PCBs are measurable in the blood of nearly 80% of Americans over age 50 years
(Shanahan et al. 2015). Hence, exposure to PCBs has been proposed to disrupt
developing neuronal circuits that may cause developmental brain disorders such
as learning disorders (LD), ADHD, and autism.
Endothelial cells of the blood-brain barrier (BBB) may provide clues in the
study of brain health, behavior, and the environment (He et al. 2014). Inhaled air
pollutants can disrupt the BBB by inducing pro-inflammatory cytokines that act on

30

endothelial cells (Genc et al. 2012). We have shown evidence for how PCBinduced reactive oxygen species (ROS) may contribute to cerebral vascular
phenotype

changes

with

the

goal of

understanding

consequences of

environmental exposures have on the BBB (Das and Felty. 2015). Toxic chemical
exposures can change brain gene expression through regulatory epigenetic
mechanisms involving alterations in DNA methylation and histone acetylation.
Evidence from animal studies show that epigenetic programming by fetal exposure
to toxicants has long-lasting consequences for gene expression in the brain as well
as behavior (Kundakovic et al. 2015). Epigenetic changes in ID3 have been
associated with maltreatment of children as well as demonstrated as a predictor
for depression (Weder et al. 2014). Epigenetic biomarkers in peripheral tissues
(blood, saliva, or buccal cells) may be useful to predict neurodevelopmental
disorders in humans. Exposures to prenatal stress, famine, and pollution/toxins,
factors known to affect brain development, have been associated with epigenetic
variation in human peripheral tissues (Perera et al. 2011). Based on these
evidences, we postulate that ID3 can be a useful biological marker of epigenetic
perturbations caused by toxic chemical exposure in children/adolescents (Figure
1.5).
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Figure 1.5 ID3 signaling pathway proposed in development of Autism Spectrum Disorder. Summary of
ID3 involvement shows regulation of various genes causing changes in various processes such as modulation
of synapses, circadian rhythm signaling, and collagen formation/stability.

Kidney disease. Lipoprotein abnormalities have been reportedly linked to renal
dysfunction in chronic kidney disease patients. Nackiewicz et al reviewed the
prominent characteristics of kidney disease previously stated in ApoE-/-ID3-/double knockout mice; and show that ID3 in hyperlipidemic mice directly effects
vulnerability to kidney disease. ID3 deficiency may intensify CXCL1 production by
glomerular cells in response to inflammatory lipids and the resulting macrophage
recruitment. Because ID3 is present in multiple cell types, it is also conceivable
that other glomerular cells lacking ID3 may contribute to cytokine production in vivo
(Tenger and Zhou. 2003). Therefore, the reno-protective effect of ID3 may be
through regulation of local chemokine production. ID3 is known to directly interact
with more than 30 different transcription factors (Lynn et al. 2010). Noticeably, a

32

change in the ID3 function may impact a wide range of protein-protein interactions
with potentially significant consequences (Nackiewicz et al. 2014). In dissimilarity
to the findings of Nachkiewicz et al, in ApoE-/-ID3-/- mice with glomerulonephritis,
the hyperlipidemic ID3-/- mice did not express meaningful increase in glomerular
immune complex deposition associated to hyperlipidemic WT mice. Apoliprotein E
deficiency is known to cause enlarged immune responsiveness (Zhao et al. 2016)
and these results add significance to the study in dissecting the effects of ID3 alone
on kidney disease.
Clinical studies deliver indication for the relationship between lipids and
chronic kidney disease. Nevertheless, they fail to elucidate why certain individuals
(in the absence of diabetes or MetS) are probable to develop chronic kidney
disease (Liu et al. 2012). Increased susceptibility to atherosclerosis has been
reported to be associated with an ID3 single nucleotide polymorphism (SNP)
(Doran et al. 2010). The overall preliminary findings in humans suggest a
significant association between the same ID3 SNP and proteinuria, specifically
influenced by small low density lipoproteins (p=0.0024) (Tenger and Zhou. 2003).
C57BL/6 male mice on high fat diets (60% calorie from fat) develop MetS
connected

with

obesity,

elevated

plasma

glucose,

proteinuria

and

glomerulonephritis (GN) and this may be due to decrease in renal AMP activated
protein kinase, a cellular energy sensor (Declèves et al. 2011). However, C57BL/6
female mice on high fat diets develop GN and proteinuria only in the absence of
ID3 suggesting distinct pathogenic mechanisms between females and males.
Examining molecular mechanisms in mice has recognized ID3 as a unique
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transcription factor that may contribute to kidney disease and provide mechanistic
links between atherosclerosis, hyperlipidemia, and kidney disease in humans. A
summary of ID3 pathway contributing to chronic kidney disease is shown in Figure
1.6.

Figure 1.6 ID3 involvement in kidney disease. Summary illustration shows a link to hyperlipidemia and
atherosclerosis.

Cancer. Deregulation of ID genes are reported in in human cancers such as nonsmall cell lung cancer (NSCLC) and colon cancer. ID3 contributes in generation of
hematopoietic

stem

and

progenitor

cells

(HSPC)

associated

with

myeloproliferative disease (MPD) (Keller, NCI Division of Basic Sciences). ID1 and
ID3 associated with the tumor promotion and metastasis (Castanon. 2013). Poor
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response to chemo-radiotherapy have been reported in NSCLC patients with
elevated ID1 and ID3 protein expression (Castanon et al. 2013). Regulation of p21
by ID1 and ID3 has been seen as the vital mechanism inhibiting the accumulation
of additional DNA damage and subsequent functional low energy of colon-initiating
cells (CC-ICs). Genetic silencing of ID1 and ID3 increases chemotherapy
sensitivity in CC-ICs suggesting that these molecules allow cancer cells to be drug
resistant (O’Brien et al. 2012). Summary illustration of ID3 signaling involved in
various cancer pathways is shown in Figure 1.7.

Figure 1.7 ID3 involvement in various types of cancer. Summary of ID3 signaling pathways involved in
Colon and Lung Cancer (Left panel). ID3 contribution to tumor angiogenesis in brain cancer (Right panel).
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Glioblastoma multiforme (GBM) tumors contain glioma stem cells or GSCs which
are an implicated for glioma resistance to treatment (Bao et al. 2006; Nakano and
Kornblum. 2006; Chalmers. 2007; Esposito et al. 2012; Phi et al. 2013). ID3 is also
shown to be connected with medullobastoma in children (Phi et al. 2013). Inhibition
of

ID3

reduced

proliferation,

migration,

and

increased

apoptosis

of

medullobastoma cells. Potential molecular mechanisms of ID3 in brain cancer are
shown in Figure 1.8.

Figure 1.8 ID3 and brain cancer mechanisms. Signaling pathways of ID3 involved in brain cancer are
summarized in the illustration.

Bone Disease. Osteogenesis imperfecta (OI) is a condition of fragile or brittle
bones that break easily. OI affects 1 in 15,000 live births resulting in recurrent
fractures and reduced mobility, with significant influence on quality of life
(Balasubramanian et al. 2016). BMPs (bone morphogenetic proteins) are
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morphogenetic signaling molecules vital for embryonic modelling. To find
molecular understanding into the effect of BMPs on morphogenesis, Hollnagel et
al examined novel genes directly activated by BMP signaling. CDM (chemically
distinct growth medium)-cultured ES cells reacted very stringently to stimulation by
numerous activin A, mesoderm inducers (BMP2/4), as well as fibroblast growth
factor (Hollnagel et al. 1999). Using cDNA cloning, six BMP target genes were
recognized. These include ID3, which exhibited convincing mRNA initiation, and
the relatively stimulated Cyr61, DEK, and eIF4AII genes, as well as a gene
translating a GC-binding protein. Alongside ID1, ID2, and ID3 genes were initiated
by BMP4 in both ES cells and arrangement of various cell lines. ID genes encode
negative regulators of basic helix-loop-helix transcription factors. In vivo, ectopic
expression was observed of ID3 and Msx-2 mRNAs in Ft/1 embryos at intersecting
regions of ectopic Bmp4 misexpression. As a result, Hollnagel et al proposed that
the target genes of BMP4 signaling demonstrated here are part of BMP-stimulated
initial processes of mammalian development. The expression arrangements of
Msx-1, Msx-2, c-jun, ID1, ID2, and ID3 in normal mice versus those lacking in
BMP2, BMP4, and BMP2/4-type I receptor will be of distinctive interest to compare.
The promoters of the genes recognized in the analysis will aid as valuable tools to
illustrate the molecular governing circuits that are overseen by BMP signaling
(Hollnagel et al. 1999).
ID proteins, including ID1, ID2, and ID3, are involved with essential
binding factor α-1 (Cbfa1) to trigger debilitated transcription of the osteocalcin
(OCL) and alkaline phosphatase (ALP) gene, commanding to weakened ALP
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action and osteocalcin (OCL) production. ID acts by hindering the specificsequence binding of Cbfa1 to DNA and diminishing the expression of Cbfa1 in cells
experiencing osteogenic differentiation (Luan et al. 2008). Summary illustration of
ID3 signaling in OI or brittle bone disease shown in Figure 6. p204, an interferoninducible protein that acts with both Cbfa1 and ID2, debilitated the ID2-mediated
inhibition of Cbfa1-induced ALP action and OCL production. Luan et al establish
that p204 interrupted the binding of ID2 to Cbfa1 and facilitated Cbfa1to bind to the
promoters of its target genes. Furthermore p204 stimulated the translocation from
nucleus to the cytoplasm and enhanced the degradation of ID2 by ubiquitin–
proteasome pathway during osteogenesis. Nucleus export signal (NES) of p204 is
necessary for the p204-enhanced cytoplasmic translocation and degradation of
ID2, since a p204 mutant-requiring NES lost these activities. Taken together, ID
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proteins help to shape a regulatory circuit and take part to control osteoblast
differentiation (Luan et al. 2008).

Figure 1.9 ID3 involvement in brittle bone disease pathogenesis. ID3 regulates various genes leading to
osteoblast differentiation, which can contribute to osteogenesis imperfecta as described in the summary
illustration.

ID1 and ID3 function to regulate bone metabolism in vivo (Maeda et al.
2004). ID1/ID3 heterozygous knock out mice, showed that the thickness of
calvarial junctions was attenuated by more than 50% (Maeda et al. 2004).
Suppression of proliferation and mineralization in osteoblasts resultant from
ID1/ID3 heterozygous knock out mice was proposed as a mechanism. Moreover,
ID1/ID3 heterozygous knock out mice inhibited BMP-stimulated bone development
in-vivo. Hence, ID1 and ID3 are critical regulators that support bone formation in
vivo (Maeda et al. 2004).

39

The connection between mechanisms of MetS and bone mineral density
(BMD) is controversial (Muhlen et al. 2007). Muhlen et al examined the association
of MetS with osteoporosis, osteoporotic fractures, and BMD. MetS was associated
with decreased, not increased BMD. Frequency of osteoporotic non-vertebral
breakages was greater in members with MetS. MetS may be an additional risk
factor for osteoporotic fractures (Muhlen et al. 2007). Occurrence of MetS at
reference was 23.5% in men and 18.2% in women. Age-adjusted analyses
demonstrated in both men and women with MetS had increased BMD at total hip
when compared to those without MetS (p<0.001 and p=0.01, respectively). Men
not women with MetS furthermore had greater BMD at femoral neck (p=0.05).
Subsequently modifying for BMI, these connections were inverted, such that MetS
was linked with decreased and not increased BMD. Occurrence of osteoporotic
non-vertebral breakages was increased in participants with MetS. The connection
of MetS with increased BMD was explained by the increased BMI in those with
MetS (Muhlen et al. 2007).

Autoimmune Diseases. MetS has been involved in autoimmune diseases. One
particular autoimmune disease is Primary Sjögren’s syndrome (pSS), which is
primarily categorized by inflammatory association of the exocrine glands important
to dry eye and mouth. Numerous organ systems can be disturbed which can cause
a wide variety of extra-glandular indicators, such as small airway disorders,
multiple sclerosis-like disease, peripheral neuropathy glomerulonephritis, and
lymphoma (Maeda et al. 2004). pSS predominately affects females (9:1), with a
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frequency in the overall population from 0.1 to 0.6 %. Studies evaluating patients
with rheumatoid arthritis (RA) (Sakurai et al. 2004) and systemic lupus
erythematosus (SLE) (Sinicato et al. 2013) have shown that inflammation plays a
role in the progression of hypertension, diabetes mellitus, and MetS (Pereira et al.
2009).
The ID3 gene is involved in the growth and function of B and T cells.
Deficient ID3 mice develop autoimmune disease comparable to human Sjögren’s
syndrome (pSS). Together B and T lymphocytes have been involved to contribute
to the disease phenotype in this model (Guo et al. 2011). The up-regulation of ID1
and ID3 genes has been reported in patients with rheumatoid arthritis (RA)
(Sakurai et al. 2001). Elevated expression of ID1 and ID3 in endothelial cells has
been proposed to contribute to severe angiogenesis found in RA.

Conclusion
We have comprehensively reviewed the existing evidence to illustrate the
association between ID3 and metabolic perturbations. Furthermore, we extended
this understanding of how ID3 and metabolic perturbations by environmental
factors such as EDCs can modify chronic disease risk and health outcomes. ID3
has been seen to interact with multiple diseases such as cancer, vascular,
neurological, autoimmune, & bone. Epidemiological and animal model studies
have shown connections between ID3 and metabolic perturbations in chronic
disease. Research is warranted to better define the influence of EDCs to ID3induced metabolic perturbations. This may lead to novel pathways for how the
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interaction of ID3, EDCs, and metabolic disorders exacerbate complex chronic
disease; and can help public health professionals control these metabolic
disorders.
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CHAPTER III
MANUSCRIPT 2
Association of PCB exposure in Peripheral Arterial Disease (PAD) Among the U.S.
Population: NHANES 1999-2004
Background. Peripheral arterial disease (PAD) is a subclinical hallmark of
coronary artery disease and identifies asymptomatic individuals at high risk for
cardiovascular disease events. Current reports have shown association with a
number of chemicals suspected to act as endocrine disruptors (EDs) by emulating
synthetic or natural estrogen resultant in an increase in disease risk such as
cancer,

cardiovascular

&

vascular,

and

neuro-degenerative

disorders.

Polychlorinated biphenyls (PCBs) have been recognized as an endocrine disruptor
due to their capability to affect & interfere with reproductive function and
development in animals and humans by increasing estrogen activity or blocking
estrogen action. Recent animal studies have suggested that PCB exposure may
have a role in several mechanisms involved in the development of CVD including
oxidative stress, vascular & endothelial dysfunction, weight gain, and insulin
resistance. We conducted an Environmental-Wide Association Study (EWAS), in
which epidemiological data are systematically and compressively interpreted in a
method corresponding to a Genome Wide Association Study (GWAS).
Objectives. The purpose of this study is to examine association between exposure
to PCBs & peripheral arterial disease (PAD) in a nationally represented sample of
the U.S. population.
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Methods. We utilized participants in the National Health and Nutritional
Examination Survey (NHANES) 1999–2004. We estimated associations between
exposure to polychlorinated biphenyls (PCBs) and PAD (ankle–brachial index <
0.9) using complex survey and logistic regression models adjusted for potential
confounders.
Results. Analysis demonstrated higher geometric levels of all 6 PCB congeners
in both PAD diagnosed participants and defined AS participants when compared
to the rest of the population. Furthermore PCB153 was shown to have the highest
geometric mean amongst all PCB congeners in both participants diagnosed with
PAD (53.38 ng/g) and AS defined participants (38.66 ng/g). Furthermore adjusted
models for PAD confounders (diabetes, smoking, & alcohol use), with gender, age,
and race showed significant association with higher exposure of PCBs and
increased risk of PAD and AS.
Conclusion. Our results suggest an association between environmental exposure
to polychlorinated biphenyls (PCBs) & increased risk of peripheral arterial disease
(PAD) and atherosclerosis (AS) among the U.S. population. Although the use of
PCBs have been discontinued, exposure via the environment still remains to pose
threats on the general population’s health.
Key words: ankle–brachial index, endocrine disrupting chemicals, NHANES,
peripheral arterial disease, polychlorinated biphenyls, vascular disease
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Introduction
Humans are exposed to a variety of environmental exposures and these
exposures may interact with one another to modify health risk outcomes. The
cardiovascular system is a significant target of these environmental exposures via
genomic and non-genomic pathways (Chambliss et al., 2002). The estrogen
receptor (ERα/β) has been shown in endothelial cells, human coronary arteries,
and cardiomyocytes (Kim-Schulze et al., 1996; Yang et al., 2004). Peripheral
arterial disease (PAD) can lead to lasting disability but general diagnosis of the
disease frequently appears late in the process. The first nationally representative
community survey done in the U.S. sponsored by the PAD coalition established
75% of respondents were unaware PAD existed and the remaining 25% knew
minimal correct information (Hirsch et al., 2007). Previous studies reported an
association between Bisphenol A (BPA), an endocrine disrupting chemical
produced in very large volume (>2 million metric tons manufactured globally in
2003) and used in the creation of polycarbonate plastics and containers used for
food and beverages (Vandenberg et al., 2009). Nevertheless, the association of
other endocrine disrupting chemicals with cardiovascular disease risk has never
been without debate.
One particular compound that has been known to show estrogenic-like
attributes are polychlorinated biphenyls (PCBs). We previously demonstrated that
planar and co-planar PCBs induce the expression of different genes compared to
estradiol. Furthermore PCBs can promote vascular lesion formation by activating
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gene networks involved in endothelial cell adhesion, cell growth, and proinflammatory molecules which were dissimilar from natural estrogen. (Felty et al.,
2010). Peripheral arterial disease (PAD) is a subclinical measure of atherosclerotic
vascular disease (Newman et al. 1993) that is an independent predictor of
following CVD incidence (Murabito et al. 2003; Newman et al. 1993). Criqui et al.
(1992) reported that individuals among originally free of CVD, an ankle–brachial
index (ABI) of < 0.9 was associated with a hazard ratio of 6.6 for future risk of death
from coronary heart disease even after adjusting for cardiovascular risk factors
including age, sex, body mass index (BMI), smoking, and high cholesterol levels.
Guidelines (American Diabetes Association 2003; Hirsch et al. 2006) exist for
defining PAD based on the ABI, which can be measured even in large populationbased studies (Selvin and Erlinger 2004).
In this study, we examined the independent association between 6
individual PCBs, the sum of non-dioxin-like PCBs, and the sum of dioxin-like-PCBs
with diagnosis of peripheral arterial disease and participants defined with
atherosclerosis in the NHANES (National Health and Nutrition Examination
Survey) in three year cycles: 1999 – 2000, 2001 – 2002, and 2003 – 2004. The
aim of this study is to asses: 1) the mean PCB levels in PAD defined participants
and atherosclerosis compared to non-diagnosed participants; and 2) the
association between higher PCB exposure and increased risk of PAD/AS.
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Methods
Study design and population. The current study is based on data from NHANES
1999-2004. NHANES survey includes a stratified multistage probability sample
representative of the civilian non-institutionalized U.S. population. Selection was
based on counties, blocks, households, and individuals within households and
included the oversampling of non-Hispanic blacks and Mexican Americans in order
to provide stable estimates of these groups. Participants provided written informed
consent before their participation. Furthermore approval was obtained from the
Human Subjects Committee in the U.S. Department of Health and Human
Services. Measurements of ABI, a subclinical measure of atherosclerosis (Criqui
et al. 1992; Newman et al. 1993), were obtained for the subsample of participants
≥ 40 years of age. The current study sample consisted of participants ≥ 40 years
of age among whom polychlorinated biphenyls was available. This resulted in
participants (461), of whom had PAD and participants (390) whom were indicated
as having atherosclerosis. Subjects who were excluded because of missing
covariates were in general similar to the NHANES cohort in terms of age, sex,
race/ethnicity, and education (data not shown). Secondary analysis of the
nationally collected data was done using variables of interest, which were only
measured concurrently during the three NHANES cycles from 1999-2000, 20012002, and 2003-2004. NHANES uses a multifaceted sampling design (multistage,
probability, cluster and stratified) for continuous collection and release of 2-year
cross-sectional data sets. Approval for these questionnaires, age, appropriate
examinations and laboratory testing were given to NHANES by the CDC/ATSDR
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institutional review board of the CDC. The current study was considered exempt
from review by the local institutional review board.
Peripheral Arterial Disease (PAD) identification. The NHANES ABI is routinely
calculated by their computer system and verified by the National Center for Health
Statistics before data release. Systolic pressure is measured on the right arm
(brachial artery) and both ankles (posterior tibial arteries). If the participant has a
rash or open wound on the right arm, dialysis shunt, right-sided radical mastectomy
or any additional condition that would interfere with accurate measurement or
cause discomfort to the participant, the left arm is used for the brachial pressure
measurement. Systolic blood pressure is measured twice at each site for
participants aged 40-59 years and once at each site for participants aged 60 years
and older. If a health technician is unable to acquire a reading at a site they may
attempt an additional reading at the same site after a short-term resting period.
The right ABPI was obtained by dividing the mean systolic blood pressure in the
right ankle by the mean blood pressure in the arm. The left ABPI was obtained by
dividing the mean systolic blood pressure in the left ankle by the mean blood
pressure in the arm. The mean blood pressure value for the arm and ankles are
computed based on the first and second reading at each site. Since the second
reading for all participants 60+ years of age is missing the mean values are in fact
the first recorded blood pressure reading at a site. This may also be true for 40-59
year old participants who have a missing value for the first or second blood
pressure reading. Individuals are excluded from the exam if they have bilateral
amputations or weigh over 400 pounds (due to equipment limitations). In addition
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to these exclusion criteria, some participants who were eligible for the exam (40
years of age and older) might not have received the exam due to various reasons:
1) casts, ulcers, dressings, or other conditions of the participant interfered with
testing, 2) participant could not understand the test instructions, 3) participant
became ill and the test could not be performed, 4) there was an equipment failure,
5) participant refused, 6) participant came late or left early from the MEC and the
LED exam could not be performed, or 7) some other reason. As a result, these
eligible individuals will have missing data for the ABPI variables. PAD was defined
as an ABI <0.7. Values 0.9 < ABI < 1.3 were considered normal. Measurements
0.7 < ABI < 0.9 were defined as indication of atherosclerosis as seen in Table 2.1.
ABI Value
ABI < 0.7
0.7 < ABI
<0.9
0.9 < ABI <
1.3

Reading Interpretation
Peripheral Arterial Disease (PAD)
Atherosclerosis (AS)
Normal

Table 2.1 ABI (Ankle-Brachial Index)

Polychlorinated Biphenyl (PCBs) measurements. Individual PCB congeners
were measured through blood serum concentration in a demonstrative, random
one-third subsample of people 12 years of age older in three survey cycles: 1999
- 2000, 2001 – 2002, and 2003 – 2004. Each survey cycle sampled for various
PCB congeners. NHANES sampled for 22 PCB congeners in the 1999 – 2000
survey, 34 PCBs congeners in the 2001-2002 cycle, and 38 PCB congeners in the
2003-2004 cycle. PCB congeners were measured in blood serum by highresolution gas chromatography/isotope-dilution high-resolution mass spectrometry
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(HRGS/ID-HRMS). Both wet-weight and lipid adjusted values for each sample,
corrected for sample weight and analyte recovery was provided by NHANES.
However we used lipid adjusted values in our analysis. Results for PCBs are
reported on a whole weight (ng/g or ppb) and a lipid-adjusted basis (ng/g or ppb).
Laboratory methods were consistent between survey cycles and are fully available
online (CDC 2013b). A detection limit variable (LOD) is specified for all PCB
congeners in the dataset. The variable LOD has two numerical values: “1”
designates that the results was below the limit of detection and “2” designates that
the results was equal to or above the limit of detection. To account for bias with
PCBs below the LOD, we selected 6 individual PCB congeners that were
represented & available from 1999 – 2004 and had concentrations above the LOD
in at least 60% of the study subjects. The overall analysis explored the association
between peripheral arterial disease variables in the U.S. population using the
following 6 PCB congeners: 2,2’,3,4,4,5,5’-heptachlorobiphenyl (PCB180),
2,2’,4,4’,5,5’-hexachlorobiphenyl
(PCB138),

2,3’,4,4’,5-

(PCB153),

2,2’,3,4,4’,5-hexachlorobiphenyl

pentachlorobiphenyl

(PCB118),

2,2’4,4’,5-

pentachlorobiphenyl (PCB99), and 2,4,4’,5 tetrachlorobiphenyl (PCB74). We also
conducted analysis on the sum of dioxin-like PCBs (074 and 118) and non-dioxinlike PCBs (099, 138,153,180).
Covariates. We considered a variety of potential confounders based on wellestablished risk factors for peripheral arterial disease and review of the literature.
The resulting potential confounders were either taken as a laboratory
measurement or self-reported in the questionnaire interviews. The demographic
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variables of gender (male/female), race (Mexican American, Other Hispanic, NonHispanic White, Non-Hispanic Black, and other race) and age (≥40-59, 60-74, and
≥ 75) were obtained during the NHANES home interview (CDC, 2012). Others
obtained include: smoking, alcohol use (yes/no), BMI (18.5 to < 25, 25 to <30, ≥
30), diabetes (yes/no), estradiol levels, sex hormone binding globulin,
testosterone, education, and annual income.
Statistical Analysis. All statistical analysis were performed using SAS 9.4 (SAS
Institute Inc., Cary, NC, USA). These analyses used 5% significance level (p≤
0.05). We used logistic regression models to calculate odds ratios (ORs) and their
95% CI (confidence intervals) to investigate the risk between PCBs and peripheral
arterial disease. According to the National Center for Health Statistics guides a six
year subsample weight was calculated to adjust for oversampling of minority
groups in the merged 1999-2004 NHANES data cycles (CDC 2013b). Non-missing
values for serum concentrations below the LOD were assigned a serum level of
the LOD divided by the square root of two. In our analysis, all lipid adjusted serum
PCB concentrations were log transformed to satisfy normality assumptions.
Participants were categorized as the following methods depending on data
analysis: < LOD vs. ≥ LOD; < LOD to 50th percentile vs. ≥ 50th percentile; and <
LOD to 50th percentile vs. 50th percentile to 75th percentile vs. ≥ 75th percentile.
We also conducted separate analyses on all participants with serum PCB levels >
LOD where PAD & AS cases were compared with normal cases. Significance was
set at p < 0.05 for all analyses.
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We utilized survey means analysis (PROC SURVEYMEANS) to account for
the complex sampling design of NHANES and to obtain weighted means, 95%
confidence intervals, and standard errors of individual PCBs, the sum of dioxin-like
PCBs, and the sum of non-dioxin-like PCBs. A two-sided student t-test was
calculated using PROC SURVEYREG to test if the mean PCB levels between
participants who were identified with PAD, AS, and normal participants were
significantly different. Geometric mean (GM) PCB levels and geometric standard
errors (GSE) were reported for peripheral arterial disease (PAD) status,
atherosclerosis (AS) status, age at interview, and race/ethnicity for all participants
with individual serum PCB levels. Computational mean serum levels of dioxin-like
and non-dioxin-like PCBs and 95% CIs were reported for PAD status and select
confounding variables. Age was divided into three groups (≥ 40-59 years, 60-74
years, and ≥ 75 years) that were selected based on the age distribution of PAD
cases, AS cases, and normal cases in the population. Race/ethnicity was divided
into five groups (Mexican American, other Hispanic, Non-Hispanic White, NonHispanic Black, and other race). We furthermore calculated both crude and age
standardized GMs for PAD cases and non-cases in the population with PCB levels
above the LOD. We used the direct technique for age adjustment provided by the
CDC (CDC 2014).
Results
Descriptive Statistics. The study population includes 6,624 participants ≥ 40
years of age. Among the 6,624 participants, 461 (6.96%) were defined with PAD,
390 (5.89%) for atherosclerosis (AS), & 5773 (87.15%) were defined as normal
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(Table 2.2). Participants were equally distributed among gender: males – 3,489
(49.77%) to females – 3,135 (50.23%). The majority of the participants in each of
the categories were predominantly Non-Hispanic White: 268 (3.72%), 236
(4.90%), and 3125 (69.64%) respectively. Participants in age group 60-74 years
old were over-represented with defined PAD (199) and ≥ 40-59 years old with
atherosclerosis (180). When asked if PAD identified participants ever smoked 72
(1.84%) said “yes,” 10 (0.24%) said “sometimes,” and 150 (3.68%) said “no.”
Various hormone levels were also assessed. Estradiol levels between 5 -95 pg/mL
were overrepresented 21 (3.18%) for participants with PAD; 31 (9.20%) for
participants defined with AS; and 323 (85.44%) for normal participants. For sex
hormone binding globulin (nmol/L) ranges from 0.350 – 90 nmol/L were most
represented by the population: 20 (2.88%) for PAD identified participants; 31
(9.31%) for participants with AS; and 306 (82.69%) normal participants. Lastly
testosterone levels (ng/mL) were also assessed for the population. Measurement
range from 0.020 – 9 ng/mL were overrepresented. Participants with PAD
represented 22 (3.24%) participants; AS participants with 32 (9.36%); and 318
(84.49%) for normal participants.
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Table 2.2 Descriptive statistics for PAD & selected covariates among participants ≥ 40 years
of age, NHANES 1999 – 2004.
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Estimated percent distribution after applying NHANES sampling weights
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Table 2.3 presents GMs and GSE of PCB concentrations (lipid-adjusted)
by PAD status, AS status, and normal status. GM PCB levels were demonstrated
as higher for all 6 PCB congeners for both participants defined with PAD as well
as participants identified with AS when compared to the normal population (Table
2.3). Overall GM levels of PCBs ranged from 13.47 ng/g (PCB074) being the
lowest and 53.38 ng/g (PCB153) being the highest in participants with PAD.
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Furthermore it was demonstrated that 6.19 ng/g (PCB099) and 38.66 ng/g
(PCB153) were demonstrated as the lowest and highest GM levels in AS
participants.

Table 2.3 Geometric Mean PCB levels (ng/g) above the LOD by PAD status
among participants ≥ 40 years of age, NHANES 1999-2004.
Cases/Non-Cases
Analyte₁
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

ABI < 0.7* 0.7 < ABI <0.9*
65
57
40
58
69
62

49
76
75
76
66
72

Geometric Mean₂ (ng/g) (GSE)
0.9 < ABI < 1.3*
2871
3767
2866
3794
3803
3800

ABI < 0.7
13.47 (8.80, 20.61)
9.95 (7.078, 14.00)
15.02 (8.94, 25.24)
37.05 (28.04, 48.97)
53.38 (40.68, 70.04)
42.13 (33.00, 53.78)

0.7 < ABI <0.9
8.82 (7.15, 10.88)
6.19 (5.35, 7.16)
10.53 (8.20, 13.52)
25.18 (20.48, 30.96)
38.66 (30.64, 48.78)
31.11 (23.84, 40.60)

0.9 < ABI < 1.3

7.82 (7.54, 8.11)
5.70 (5.53, 5.87)
8.90 (8.56, 9.26)
19.79 (19.11, 20.49)
27.68 (26.70, 28.70)
20.50 (19.71, 21.31)

1 Lipid Adjusted and log transformed polychlorinated biphenyls (ng/g)
2 Geometric Means calculated after applying NHANES sampling weights
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Figure 2.1 Geometric mean PCB levels (ng/g) by PAD status for participants ≥ 40 years of age, NHANES
1999-2004.

Geometric mean PCB levels were also examined by age group of
participants (Table 2.4). The overall GM levels of PCBs increased significantly in
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PAD participants as age group progressed except PCB099 which demonstrated a
non-consistent trend (10.04 ng/g vs. 8.82 ng/g vs. 18.99 ng/g). In the first age
group (≥ 40 – 59) GM levels of PCBs are demonstrated to be higher in PAD defined
participants when compared to normal participant levels. Additionally the same
trend is shown when comparing AS participants to the normal group. In the second
age group (60 – 74 years old), participants had higher GM PCB levels of congeners
with the exception of PCB congener 180 that demonstrated lower GM PCB levels
in normal participants when compared to PAD participants (Table 2.4). The
population who were AS defined when compared to the normal population were
shown as being higher. In the third age group (≥ 75 years old) all PCB congeners
were shown to be higher in PAD identified participants when compared to normal
participants. Furthermore higher PCB levels of participants whom were at defined
AS participants were demonstrated with PCB congeners 74 and 118. Interestingly
PCB 099, 138, 153, and 180 were shown to have higher PCB GM in normal
participants when compared to AS participants.
Table 2.4 Geometric Mean PCB levels (ng/g) above the LOD by peripheral arterial disease
status by age groups, NHANES 1999-2004

Analyte₁
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

ABI < 0.7*

Age: ≥ 40-59
0.7 < ABI <0.9*

9.41 (2.59)
10.04 (2.52)
9.01 (2.13)
36.90 (9.13)
52.80 (10.55)
38.98 (8.45)

7.10 (0.73)
5.54 (0.47)
8.48 (1.15)
22.75 (2.54)
35.51 (4.38)
28.80 (4.69)

Geometric Mean₂ (ng/g) (GSE, n)
Age: 60-74
0.9 < ABI < 1.3*
ABI < 0.7
0.7 < ABI <0.9 0.9 < ABI < 1.3
6.58 (0.14)
5.14 (0.10)
7.56 (0.18)
18.20 (0.39)
25.61(0.57)
18.91 (0.46)

14.78 (0.50)
8.82 (0.30)
17.42 (0.76)
39.46 (1.20)
58.18 (1.59)
48.13 (1.19)

19.87 (2.53)
8.69(1.11)
22.96 (3.32)
40.84 (4.63)
64.95 (8.62)
50.25 (6.84)

12.12 (4.02) 40.06 (5.46)
7.61 (2.53)
18.99 (3.13)
13.18 (5.67) 54.77 (10.36)
36.78 (7.43) 64.60 (8.86)
55.36 (10.15) 97.05 (12.95)
49.84 (7.19) 65.00 (9.02)

¹ Lipid Adjusted and log transformed polychlorinated biphenyls (ng/g);
² Geometric Means calculated after applying NHANES sampling weights
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)
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ABI < 0.7

Age: ≥ 75
0.7 < ABI <0.9

0.9 < ABI < 1.3

25.53 (5.54)
10.27 (2.97)
50.02 (13.18)
46.38 (11.75)
63.22 (10.94)
44.38 (10.29)

22.32 (1.05)
11.65 (0.52)
24.40 (1.32)
51.76 (2.06)
75.76 (2.71)
60.77 (2.08)

Figure 2.2.1 Geometric mean PCB levels (ng/g) by PAD status for participants ≥ 40-59 years of age,
NHANES 1999-2004.

Figure 2.2.2 Geometric mean PCB levels (ng/g) by PAD status for participants 60 - 74 years of age,
NHANES 1999-2004.
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Figure 2.2.3 Geometric mean PCB levels (ng/g) by PAD status for participants ≥ 75 years of age,
NHANES 1999-2004.

Table 2.5 presents age standardized GMs and GSEs of PCBs by
race/ethnicity in participants with individual concentrations of PCBs above the
LOD. Ethnic backgrounds that were demonstrated to have higher PCB
concentrations when having PAD compared to normal participants include:
“Mexican American,” “Non-Hispanic White,” “Other Race,” and “Non-Hispanic
Black.” “Other Hispanic” demonstrated lower levels of PCB concentrations in PAD
participants when compared to normal participants. Furthermore participants with
AS in ethnic groups include: “Mexican American,” “Non-Hispanic White,” “NonHispanic Black,” and “Other Race” demonstrated higher levels of PCBs when
compared to normal participants. “Other Hispanic” AS participants showed lower
PCB concentrations when compared to normal participants.
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Table 2.5 Age standardized geometric mean PCB levels (ng/g) above the LOD by
race/ethnicity among participants ≥ 40 years old PAD by age groups, NHANES 1999-2004.
Geometric Mean₂ (ng/g) (GSE, n)

Analyte₁
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

Analyte
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

Analyte
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

ABI < 0.7*

Mexican American
0.7 < ABI < 0.9*

0.9 < ABI < 1.3*

10.46 (6.56-16.69)
7.53 (4.97-11.43)
10.83 (6.03-19.46)
28.70 (17.25-47.72)
36.97 (23.34-58.55)
24.46 (14.99-39.90)

7.68 (5.50-10.72)
5.50 (4.28-7.08)
10.05 (6.96-14.52)
23.30 (17.39-31.21)
37.56 (28.53-49.44)
27.73 (19.04-40.41)

4.60 (4.29-4.93)
3.55 (3.35-3.77)
5.71 (5.34-6.12)
9.72 (9.02-10.47)
12.57 (11.61-13.61)
9.02 (8.25-9.87)

ABI < 0.7

Non-Hispanic White
0.7 < ABI < 0.9

0.9 < ABI < 1.3

13.17 (7.67-22.61)
9.53 (6.28-14.48)
14.54 (7.42-28.53)
35.72 (25.63-49.80)
52.22 (37.92-71.90)
42.66 (32.36-56.24)

9.05 (7.14-11.48)
6.27 (5.32-7.38)
10.78 (8.13-14.30)
26.78 (21.74-32.99)
41.52 (33.01-52.22)
33.69 (25.47-44.56)

8.45 (8.08-8.84)
5.75 (5.54-5.96)
9.13 (8.70-9.59)
20.65 (19.80-21.55)
29.32 (28.07-30.62)
22.27 (21.24-23.35)

ABI < 0.7

Other Race
0.7 < ABI < 0.9

0.9 < ABI < 1.3

10.43 (10.22-11.23)
5.77 (4.42-5.96)
10.21 (10.15-10.45)
21.21 (18.32-23.32)
30.43 (29.23-31-75)
24.42 (22.32-25.32)

11.73 (11.70-11.88)
8.02 (8.00-8.10)
11.01 (11.00-11.02)
21.70 (21.74-21.89)
40.00 (40.0-40.2)
26.20 (26.19-26.24)

5.86 (5.02-6.85)
5.64 (4.94-6.43)
8.28 (6.89-9.94)
19.01 (16.21-22.29)
26.25 (22.15-31.11)
18.28 (15.08-22.17)

Analyte
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

Analyte
PCB074
PCB099
PCB118
PCB138
PCB153
PCB180

ABI < 0.7

Other Hispanic
0.7 < ABI < 0.9

0.9 < ABI < 1.3

3.90 (3.87-4.01)
4.52 (4.10-4.35)
3.54 (3.42-3.98)
6.59 (6.43-8.42)
7.97 (3.42-8.15)
3.42 (3.14-3.88)

5.98 (2.20-16.22)
4.82 (2.65-8.77)
6.85 (1.96-23.96)
7.40 (1.84-29.80)
8.33 (1.66-41.87)
6.66 (2.01-22.04)

7.03(5.95-8.31)
5.63 (5.00-6.35)
9.81 (8.28-11.62)
19.56 (16.64-22.98)
26.36 (22.21-31.29)
18.39 (15.48-21.85)

ABI < 0.7

Non-Hispanic Black
0.7 < ABI < 0.9

0.9 < ABI < 1.3

18.56 (10.53-32.70)
14.15 (7.58-26.40)
21.73 (12.04-39.20)
54.59 (32.07-92.93)
78.34 (45.95-133.56
54.35 (30.65-96.39)

8.91 (6.61-12.00)
7.53 (5.99-9.47)
12.12 (7.94-18.51)
31.61 (14.00-71.36)
39.37 (15.94-97.22)
38.61 (15.76-94.60)

7.69 (7.07-8.36)
7.40 (6.88-7.95)
9.80 (8.87-10.82)
23.93 (22.01-26.02)
32.53 (29.82-35.49)
21.91 (20.04-23.95)

1 Lipid Adjusted and log transformed polychlorinated biphenyls (ng/g)
2 Geometric Means calculated after applying NHANES sampling weight
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal

Table 2.6 demonstrates the computational means and 95% CIs of dioxinlike serum levels of PCBs for PAD, atherosclerosis, normal, and selected
covariates in the study population. Computational means of dioxin-like PCBs were
higher in participants diagnosed with PAD (1.57 ng/g) compared to participants
without PAD (1.35 ng/g). Furthermore PCBs were lower in participants with AS
(1.33 ng/g) compared to normal participants. Mean dioxin-like PCBs increased with
age in all three groups: PAD, AS, & normal participants. Other Hispanic was
demonstrated to be the highest race diagnosed with PAD (1.68 ng/g) and NonHispanic Black with AS (1.51 ng/g). Additionally all three age groups demonstrated
a higher mean of PCB levels in both PAD participants & AS participants when
compared to normal participants.
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Table 2.6 Serum levels of dioxin-like PCBs (ng/g) in the study population, participants ≥ 40
years of age, NHANES 1999-2004.

¹ Means calculated after applying NHANES sampling weights; lipid-adjusted and log transformed PCBs
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Table 2.7 demonstrates the computational means and 95% CIs of nondioxin-like PCBs for diagnosis of PAD, AS, and normal population. Computational
means was seen higher in diagnosed PAD participants exposed to non-dioxin-like
PCBs compared to the normal population (2.18 ng/g vs.2.00 ng/g). Interestingly,
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means was seen lower in AS participants when compare to the normal population
(1.95 ng/g vs. 2.00 ng/g). Additionally all individual races/ethnicities demonstrated
higher non-dioxin-like PCB concentrations in PAD diagnosed participants when
compared to the normal population. Individual races/ethnicities including: “Mexican
American” and “Non-Hispanic Black” showed higher non-dioxin-like PCB exposure
in participants with AS when compared to the normal population.
Table 2.7 Serum levels of non-dioxin like PCBs (ng/g) in the study population, participants
≥ 40 years of age, NHANES 1999-2004
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¹ Means calculated after applying NHANES sampling weights; lipid-adjusted and log transformed PCBs
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Geometric Means and 95% CI’s of PCB levels (lipid-adjusted) are reported
in Table 2.8 for participants with PCB levels < LOD and ≥ LOD. All participants
who reported concentrations of ≥ LOD who were diagnosed with PAD had higher
GM levels of PCB congeners. Similarly, participants who reported concentrations
of ≥ LOD who were AS participants had higher PCB congener levels (074, 099,
158, and 180). PCB congener 074 had higher GM in normal participants vs. ones
who were AS participants (14.07 ng/g vs. 13.19 ng/g) and congener 118
demonstrated comparable GM levels (11.51 ng/g vs. 11.32 ng/g) (Table 2.8)

2.8 Geometric Mean PCB levels (ng/g) by PAD status among participants ≥ 40 years of age,
NHANES 1999-2004.
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Analyte₁
PCB074
< LOD
≥ LOD
PCB099
< LOD
≥ LOD
PCB118
< LOD
≥ LOD
PCB138
< LOD
≥ LOD
PCB153
< LOD
≥ LOD
PCB180
< LOD
≥ LOD

ABI < 0.7*

Cases/Non-cases
0.7 < ABI <0.9*

0.9 < ABI < 1.3*

ABI < 0.7

Geometric Mean₂ (ng/g) (95% CI)
0.7 < ABI < 0.9

0.9 < ABI < 1.3

16
29

22
47

1467
1382

4.27 (3.83-4.75)
25.70 (19.36-34.12)

4.12 (3.87-4.40)
13.186 (11.47-15.15)

3.71 (3.63-3.79)
14.07 (13.66-14.49)

11
28

13
35

1267
1322

2.85 (2.44-3.34)
21.21 (15.96-28.18)

3.35 (3.16-3.54)
10.06 (8.72-11.61)

2.63(2.57-2.70)
12.29 (11.90-12.70)

3
41

3
66

574
2250

2.39 (1.55-3.69)
18.28 (10.88-30.71)

3.63 (3.50-3.76)
11.51 (8.97-14.76)

2.94 (2.85-3.033)
11.32 (10.89-11.77)

0
58

0
76

78
3708

N/A
37.05 (28.03-48.97)

N/A
25.18 (20.48-30.96)

1.98 (1.89-2.07)
20.40 (19.72-21.10)

6
52

5
71

1080
2530

4.07 (3.65-4.54)
62.71 (49.79-78.98)

4.99 (3.18-7.84)
44.28 (36.43-53.80)

5.58 (5.39-5.78)
40.82 (39.59-42.09)

0
58

0
76

217
3571

N/A
42.13 (33.00-53.78)

N/A
31.11 (23.84-40.60)

1.53 (1.39-1.69)
22.10 (21.28-22.93)

₁ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g)
₂ Geometric means calculated after applying NHANES sampling weights
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

We also adjusted the PCB levels into the following two groups < LOD to 50th
percentile and ≥ 50th percentile (Table 2.9). Participants in the first group (< LOD
to 50th percentile) with PAD showed higher GM PCB levels compared to
participants who were defined as normal participants: PCB congener 074 (3.65
ng/g vs. 3.10 ng/g); 099 (2.85 ng/g vs. 2.61 ng/g); 118 (3.82 ng/g vs. 3.60 ng/g).
PCB congeners 138 (7.06 ng/g vs. 7.66 ng/g); 153 (6.51 ng/g vs. 9.59 ng/g); and
180 (5.78 ng/g vs. 6.99 ng/g) showed higher levels of PCB GMs in normal
participants then in participants defined with PAD. Furthermore a significant
increase was seen in the second group (≥ 50th percentile) for PCB congener 074
(17.68 vs. 11.20); 099 (13.06 vs. 8.03); 118 (28.26 vs. 14.09); 138 (45.30 vs.
35.53); 153 (64.87 vs. 50.47) 180 (51.69 vs. 41.63). GM PCB concentrations
between AS participants and normal participants were demonstrated to have little
to no change between the two groups with the exception of PCB 153 (12.94 vs.
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9.59 for < LOD to 50%; 54.29 vs. 50.47 for ≥ 50%) and PCB 180 (44.85 vs. 41.63
for ≥ 50%) (Table 2.9).
Table 2.9 Geometric mean PCB levels (ng/g) by PAD status among participants ≥ 40 years
of age, NHANES 1999-2004
Analyte₁
PCB074
< LOD to 50%
≥ 50%
PCB099
< LOD to 50%
≥ 50%
PCB118
< LOD to 50%
≥ 50%
PCB138
< LOD to 50%
≥ 50%
PCB153
< LOD to 50%
≥ 50%
PCB180
< LOD to 50%
≥ 50%

ABI < 0.7*

Cases/Non-cases
0.7 < ABI < 0.9*

0.9 < ABI < 1.3*

ABI < 0.7

Geometric Mean₂ (ng/g) (95% CI)
0.7 < ABI < 0.9

0.9 < ABI < 1.3

8
37

11
58

962
1904

3.65 (3.15-4.23)
17.68 (11.43-27.35)

3.70 (3.48-3.94)
11.04 (9.10-13.40)

3.10 (3.02-3.18)
11.20 (10.82-11.59)

11
46

13
63

1215
2549

2.85 (2.44-3.33)
13.06 (9.41-18.11)

3.35 (3.17-3.54)
7.14 (6.11-8.34)

2.61 (2.55-2.68)
8.03 (7.80-8.26)

16
30

14
55

1181
1686

3.82 (3.06-4.78)
28.26 (16.81-47.52)

4.14 (3.85-4.45)
15.26 (12.45-18.70)

3.60 (3.52-3.68)
14.09 (13.54-14.66)

11
47

16
60

1776
2018

7.06 (4.42-11.29)
45.30 (34.93-58.75)

10.48 (7.94-13.83)
34.77 (29.88-40.46)

7.66 (7.41-7.92)
35.53 (34.49-36.60)

10
49

12
64

1751
2050

6.51 (3.86-10.96)
64.87 (51.40-81.85)

12.94 (8.76-19.12)
54.29 (47.20-62.44)

9.59 (9.23-9.96)
50.47 (49.05-51.93)

11
47

15
60

1840
1953

5.78 (4.02-8.32)
51.69 (42.09-63.47)

7.67 (5.71-10.30)
44.85 (37.38-53.81)

6.99 (6.69-7.29)
41.63 (40.51-42.78)

₁Lipid adjusted and log transformed polychlorinated biphenyls (ng/g)
₂Geometric means calculated after applying NHANES sampling weights
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

We additionally divided lipid adjusted PCB GMs to three groups: < LOD to
50%, 50% to 75%, and ≥ 75% (Table 2.10). Participants in groups <LOD to 50%
demonstrated higher PCB concentrations in PAD defined participants when
compared to normal participants (PCB congeners 074, 099, 118). PCB congeners
138, 153, and 180 showed the reverse results and demonstrated higher PCB
concentration levels in normal participants when compared to the participants
defined with PAD. When comparing AS participants to normal, all PCB congeners
were higher than PCB GM levels in normal participants for < LOD to 50% (074,
099, 118, 138, 153, 180). GM PCB concentrations did not significantly differ in
group 50% to 75% for both PAD diagnosed & participants with AS when compared
to the normal group. In the final group ≥ 75%, a significant change was
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demonstrated through all the participants with PAD when compared to the normal
group. However PCB congener 180 was only shown at being higher in AS
participants compared to normal ones (Table 2.10).
Table 2.10 Serum levels of PCBs (ng/g) in the study population, participants ≥ 40 years of
age, NHANES 1999 – 2004.

ABI < 0.7*
Analyte₁
PCB074
< LOD to 50%
50% to 75%
≥ 75%
PCB099
< LOD to 50%
50% to 75%
≥ 75%
PCB118
< LOD to 50%
50% to 75%
≥ 75%
PCB138
< LOD to 50%
50% to 75%
≥ 75%
PCB153
< LOD to 50%
50% to 75%
≥ 75%
PCB180
< LOD to 50%
50% to 75%
≥ 75%

Cases/Non-cases
0.7 < ABI < 0.9*
0.9 < ABI < 1.3*

ABI < 0.7

Geometric Mean₂ (ng/g) (95% CI)
0.7 < ABI <0.9

0.9 < ABI < 1.3

8
13
24

11
19
39

962
803
1101

3.65 (3.15-4.23)
5.63 (4.91-6.44)
31.81 (24.21-41.79)

3.70 (3.48-3.94)
6.15(5.302-7.14)
15.95 (13.57-18.74)

3.10 (3.02-3.18)
6.05 (5.94-6.17)
16.83 (16.25-17.43)

11
19
27

13
41
22

1215
1621
928

2.85 (2.44-3.33)
4.43 (4.22-4.65)
21.30 (16.02-28.33)

3.35 (3.17-3.54)
5.28 (4.78-5.83)
12.38 (10.50-14.582)

2.61 (2.55-2.68)
5.41 (5.33-5.50)
15.72 (15.20-16.26)

16
4
26

14
15
40

1181
614
1072

3.82 (3.06-4.78)
5.87 (4.78-7.22)
34.52 (22.10-53.93)

4.14 (3.85-4.45)
7.04 (6.04-8.21)
19.09 (15.52-23.48)

3.60 (3.52-3.68)
7.24 (7.09-7.40)
21.64 (20.78-22.53)

11
19
28

16
25
35

1776
817
1198

7.06 (4.42-11.29)
21.63 (18.62-25.13)
75.44 (59.77-95.22)

10.48 (7.93-13.83)
20.40 (18.03-23.09)
47.29 (42.38-52.77)

7.66 (7.41-7.92)
21.70 (21.31-22.09)
54.04 (52.47-55.66)

9
11
24

11
19
39

1268
588
997

6.51 (3.86-10.96)
30.98 (26.72-35.93)
92.40 (73.10-116.79)

12.94 (8.76-19.12)
32.36 (27.87-7.58)
68.28 (61.11-76.30)

9.59 (9.23-9.96)
30.73 (30.17-31.31)
74.12 (72.12-76.17)

11
10
36

15
20
40

1840
765
1188

5.78 (4.02-8.32)
23.44 (20.60-26.68)
67.27 (56.16-80.57)

7.67 (5.71-10.30)
26.79 (23.64-30.35)
61.44 (51.93-72.715)

6.99 (6.69-7.29)
26.49 (26.03-26.96)
60.60 (59.00-62.25)

1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g)
2 Geometric means calculated after applying NHANES sampling weight
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Table 2.11 summarized adjusted odds ratios (ORs) and 95% confidence
interval (CI) models for individual PCB congeners (074, 099, 118, 138, 153, and
180) in two groups: < LOD to 50% & ≥ 50%. Adjusted models for < LOD to 50%
showed no association between PCB exposure and PAD. However adjusted
models for ≥ 50% showed significant associations for PCB congeners (074, 099,
118, 138, 153, and 180) and PAD. Table 2.12 demonstrated adjusted ORs and
95% CI models for individual PCB congeners (074, 099, 118, 138, 153, and 180)
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in three groups: < LOD to 50%, 50 % to 75%, and ≥ 75%. Adjusted models for
PAD confounders; gender and PAD confounders; age, race, and PAD
confounders; and gender, age, race, and PAD confounders showed a significant
association between exposure and increased risk of PAD in groups 50% to 75%
and ≥ 75%. Group < LOD to 50% showed no association. Table 2.13 shows
adjusted ORs and 95% CI models for individual PCB congeners in four groups: <
LOD to 50%, ≥ 50%, < LOD to 75%, and ≥ 75%. Adjusted models in groups ≥ 50%
& ≥ 75% showed association between higher exposure of PCBs and increased risk
of PAD.
In the adjusted model for PAD confounders (diabetes, smoking, & alcohol
use) at ≥ 50% & ≥ 75%, dioxin-like PCBs were significantly associated with PAD
[(OR: 2.04; 95% CI: 1.81 – 3.57), (OR:2.46; 95% CI:2.01 -11.87)] as well as nondioxin-like PCBs [(OR: 1.07; 95% CI: 1.02 – 32.59), (OR: 2.64; 95% CI: 1.62 –
10.67)] . After adjusting the model for gender and PAD confounders, dioxin-like
PCBs showed association with PAD [(OR: 1.35; 95% CI: 1.05 – 1.36), (OR: 3.35;
95% CI: 1.35 – 10.36)] as well as non-dioxin-like PCBs [(OR: 2.38; 95% CI: 2.35
– 29.40), OR: 2.59; 95% CI: 2.57 – 10.62)]. Adjusting the model for age, race, &
PAD confounders the model demonstrated dioxin-like PCBs association with PAD
[(OR: 1.95; 95% CI: 0.94 – 2.36), (OR: 2.95; 95% CI: 0.94 – 6.00)] together with
non-dioxin-like PCBs [(OR: 2.07; 95% CI: 0.96 – 12.97), (OR: 2.37; 95% CI: 0.96
– 6.97)]. After adjusting the model for gender, age, race, and PAD confounders;
dioxin-like PCBs remained significantly associated with PAD [(OR: 1.68; 95% CI:
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1.38 – 2.58), (OR: 3.88; 95% CI: 1.01 – 5.08)] as well as non-dioxin-like PCBs
[(OR: 2.09; 95% CI: 2.09– 14.10), OR: 3.01; 95% CI: 1.10 – 8.13)].
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Table 2.11 Estimated ORs & 95% CI of PAD status by concentration of PCB levels among
participants ≥ 40 years of age, NHANES 1999 - 2004
Analyte¹
PCB074
< LOD to 50%
≥ 50%
PCB099
< LOD to 50%
≥ 50%
PCB118
< LOD to 50%
≥ 50%
PCB138
< LOD to 50%
≥ 50%
PCB153
< LOD to 50%
≥ 50%
PCB180
< LOD to 50%
≥ 50%

ABI < 0.7*

0.7 < ABI < 0.9*

0.9 < ABI < 1.3*

Adjusted OR (95% CI)²

8
37

11
58

962
1904

1

1

1

1

1.61 (0.64 - 8.65)

2.72 (1.72- 4.73)

2.63 (1.63 - 11.64)

2.76 (1.75 - 11.77)

11
46

13
63

1215
2549

1

1

2.92 (1.91 - 5.92)

2.95 (1.94 - 5.95)

1
1.91 (1.60 - 3.92)

1.95 (1.94 - 2.96)

16
30

14
55

1181
1686

1

1

2.26 (0.75 - 11.26)

3.31 (1.31 - 10.32)

1
4.08 (3.08 - 9.09)

4.17 (1.16 - 9.17)

11
47

16
60

1776
2018

1

1

1.38 (2.37 - 17.39)

3.39 (2.38 - 12.40)

1
3.71 (1.71 - 7.72)

3.73 (1.72 - 6.70)

10
49

12
64

1751
2050

1

1

3.45 (1.47 - 25.66)

4.64 (2.63 - 42.65)

1
2.16 (1.95 - 31.97)

1
3.33 (1.92 - 29.94)

11
47

15
60

1840
1953

1

1

2.33 (1.52 - 19.55)

3.49 (3.47 - 30.50)

1
2.00 (1.59 - 17.02)

1
2.89 (2.87 -17.90)

Adjusted OR (95% CI)³

Adjusted OR (95% CI)⁴

Adjusted OR (95% CI)⁵

1

1

1

¹ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g)
² Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use)
³ Adjusted for Gender, & PAD confounders
⁴ Adjusted for Age, Race, & PAD confounders
⁵ Adjusted for Gender, Age, Race, & PAD confounders
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Table 2.12 Estimated ORs & 95% CI of PAD status by concentration of PCB levels among
participants ≥ 40 years of age, NHANES 1999 - 2004
ABI < 0.7*
Analyte₁
PCB074
< LOD to 50%
50% to 75%
≥ 75%
PCB099
< LOD to 50%
50% to 75%
≥ 75%
PCB118
< LOD to 50%
50% to 75%
≥ 75%
PCB138
< LOD to 50%
50% to 75%
≥ 75%
PCB153
< LOD to 50%
50% to 75%
≥ 75%
PCB180
< LOD to 50%
50% to 75%
≥ 75%

0.7 < ABI <0.9* 0.9 < ABI < 1.3*

Adjusted OR (95% CI)²

Adjusted OR (95% CI)³

Adjusted OR (95% CI)⁴

Adjusted OR (95% CI)⁵

8
13
24

11
19
39

962
803
1101

1
1.78 (1.12 - 10.13)
2.02 (1.71 - 19.73)

1
2.11 (1.09 - 4.21)
3.26 (1.45 - 6.87)

1
1.35 (0.54 - 6.95)
2.59 (0.58 - 7.60)

1
2.45 (1.04 - 4.05)
3.80 (1.39 - 6.99)

11
19
27

13
41
22

1215
1621
928

1
2.58 (1.38 - 4.59)
3.50 (2.22 - 6.51)

1
2.63 (1.62 - 3.63)
2.58 (1.57 - 3.59)

1
1.37 (0.13 - 2.85)
1.32 (0.31 - 2.34)

1
2.24 (0.44 - 3.45)
2.46 (0.35 - 2.78)

16
4
26

14
15
40

1181
614
1072

1
2.21 (1.66 - 6.68)
2.50 (2.73 - 10.75)

1
2.80 (1.80 - 5.81)
2.89 (2.88 - 6.91)

1
1.76 (0.49 - 3.51)
2.59 (2.58 - 5.60)

1
3.00 (0.68 - 4.70)
3.79 (2.77 - 5.80)

11
19
28

16
25
35

1776
817
1198

1
1.75 (1.38 - 10.39)
2.03 (1.32 - 12.74)

1
2.39 (1.39 - 9.40)
3.75 (2.33 - 19.76)

1
1.76 (1.26 - 7.47)
2.28 (1.19 - 23.09)

1
2.48 (0.47 - 5.48)
3.10 (2.07 - 26.11)

9
11
24

11
19
39

1268
588
997

1
3.69 (1.03 - 9.74)
4.81 (2.24 - 13.17)

1
5.64 (2.23 - 10.74)
6.84 (3.23 - 14.45)

1
3.07 (1.06 - 10.08)
4.81 (1.70 - 13.73)

1
3.04 (1.03 - 9.05)
4.85 (2.64 - 10.66)

11
10

15
20

1840
765

36

40

1188

1
2.67 (1.23 - 8.68)
2.95 (1.87 - 10.33)

1
2.96 (1.65 - 30.66)
3.04 (2.23 - 14.26)

1
3.25 (1.66 - 25.68)
3.92 (0.86 - 16.90)

1
3.62 (1.61 - 19.62)
3.98 (0.66 - 21.71)

¹ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g)
² Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use)
³ Adjusted for Gender, & PAD confounders
⁴ Adjusted for Age, Race, & PAD confounders
⁵ Adjusted for Gender, Age, Race, & PAD confounders
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)
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Table 2.13 Estimated ORs (95% CIs) of PAD status by concentration of dioxin-like & nondioxin like PCB levels among participants ≥ 40 years of age, NHANES 1999 – 2004
Analyte¹
Dioxin-like PCBs_50²
< LOD to 50%
≥ 50%
Dioxin-like PCBs_75²
< LOD to 75%
≥ 75%
Non-dioxin-like PCBs_50³
< LOD to 50%
≥ 50%
Non-dioxin-like PCBs_75³
< LOD to 75%
≥ 75%

ABI < 0.7*

0.7 < ABI < 0.9*

0.9 < ABI < 1.3*

Adjusted OR (95% CI)⁴

Adjusted OR (95% CI)⁵

Adjusted OR (95% CI)⁶

Adjusted OR (95% CI)⁷

4
45

6

71

69

1342

1
2.04 (1.81 - 3.57)

1
1.35 (1.05 - 1.36)

1
1.95 (0.94 - 2.36)

1
1.68 (1.38 - 2.58)

10
58

15
76

90
1288

1
2.46 (2.01 - 11.87)

1
3.35 (1.35 - 10.36)

1
2.95 (0.94 - 6.00)

1
3.88 (1.01 - 5.08)

15
61

18
55

65
1710

1
1.07 (1.02 - 32.59)

1
2.38 (2.35 - 29.40)

1
2.07 (0.96 - 12.97)

1
2.09 (2.09 - 14.10)

6
59

4
76

951
828

1
2.64 (1.62 - 10.67)

1
2.59 (2.57 - 10.62)

1
2.37 (0.96 - 6.97)

1
3.01 (1.10 - 8.13)

¹ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g)
² Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use)
³ Adjusted for Gender & PAD confounders
⁴ Adjusted for Age, Race, & PAD confounders
⁵ Adjusted for Gender, Age, Race, & PAD confounders
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Discussion
This cross sectional study representing a sample of the United States
demonstrated that higher levels of PCB concentration were associated with
participants defined with PAD and atherosclerosis in the general population. We
assessed 6 individual PCB congeners, the sum of dioxin-like PCBs, and the sum
of non-dioxin like PCBs. Overall analysis of geometric mean levels of PCBs
represented by participants identified with PAD, atherosclerosis, age, race, and
various covariates was done to assess PCB concentrations in subpopulations. All
PCB congeners showed a higher concentration level in both PAD participants and
at AS when comparing to the normal population. Although to our knowledge this is
the first study investigating PCB association with PAD and AS, our results adds
developing evidence to the environmental exposure of PCBs similar to the effects
of BPA, another type of endocrine disrupting chemical in cardiovascular disease
(Lang et al., 2008; Melzer et al., 2010). Furthermore because PAD is a subclinical
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marker for atherosclerosis, our findings may elucidate that possible effects of
PCBs on atherosclerosis may be an essential mechanism previously reporting an
association between PCB exposure and the development of obesity and obesityassociated atherosclerosis (Arsenescu et al., 2008).
Polychlorinated Biphenyls are a group of man-made organic chemicals that
consist of chlorine, hydrogen, and carbon atoms. Today PCBs can still be released
in the environment from illegal dumping of PCB wastes, burning wastes in
industrial and municipal incinerators, leaks from electrical transformers containing
PCBs, and improper or poorly maintained hazardous sites containing PCBs (EPA).
While there has not been any previously studies done in NHANES linking PCB
exposure to PAD and AS recent studies have linked exposure to BPA to peripheral
arterial disease (Shankar et al., 2012) and heart disease (Melzer et al., 2010).
Numerous lines of evidence suggest that a link between levels of PCB
concentrations and PAD and/or AS may be biologically conceivable. Significant
associations between PCBs, lipids, age, BMI, and CVD in a Native American
population demonstrate a consistency with a model in which age is considered
both a biological driving mechanism and exogenous explanatory variable
(Goncharov et al., 2008). Dioxin-like PCB 126 effects CVD risk factors on female
experimental rodents such as blood pressure, heart weight, and serum cholesterol
(Lind et al., 2004). Furthermore higher levels of PCB concentration in HDL
demonstrated links to CVD (Ljunggren et al., 2014). Previously we have reported
planar and coplanar PCBs induce expression of various genes compared to
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estradiol that have biological relevance to signaling in pulmonary vascular lesions
(Felty et al., 2010). Additionally, ID3 a molecule that has been demonstrated to be
involved in vascular diseases has provided evidence linking its vital role in
regulating both vascular endothelial cell survival and microvascular lesion
development by endocrine disrupting chemicals such as PCB153 (Das & Felty.,
2014).
Our study includes a nationally representative sample of the United States
population and provides a rigorous methodology of collecting, analyzing, and
having multiple confounding data point’s accessible to the public. (NCHS 2010a,
2010b). Further strengths include availability of biological measurements of
endocrine disrupting chemicals and oversampling of minority populations making
it possible to have a complete representation of the US population. However a
limitation that we have on our study is since it is a cross-sectional study, it makes
it difficult to validate the exposure ensued the overall outcome. Additionally
observed associations could be potentially confounded by lack of data on
geographical location of family history and/or geographic location of some
variables.
Conclusion
In a nationally representative sample of the U.S. population higher levels of
PCB exposure were associated with increased risk of PAD as well as
atherosclerosis subsequently adjusting for covariate factors. While our results
must be established in other studies, they provide preliminary evidence that
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environmental exposure to PCBs may contribute to increased risk of PAD and/or
AS.
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CHAPTER IV
MANUSCRIPT 3
Association of endocrine disrupting chemical exposure in Peripheral Arterial
Disease (PAD) Among the U.S. Population: NHANES 1999 – 2004
Abstract
Background. Recent reports have continuously shown that the human population
get exposed to a wide range of endocrine disrupting chemicals. In particular
phthalates & bisphenol A (BPA) have been detected in more than 90% of urine
and blood samples collected (Silva et al 2004; Woodruff et al 2011; Calafat et al
2008). Although previous reports from various data have demonstrated
association between phthalates & BPA with various diseases the bridge between
phthalates & BPA with peripheral arterial disease is limited.
Objectives. The purpose of this study is to examine association between exposure
to endocrine disrupting chemicals (EDCs) & peripheral arterial disease (PAD) in a
nationally represented sample of the U.S. population.
Methods. We utilized participants in the National Health and Nutritional
Examination Survey (NHANES) in 1999 - 2004. We estimated associations
between exposure to EDCs (phthalates in 1999 - 2004 & bisphenol A in 2003 –
2004) respectively and PAD using complex survey and logistic regression models
adjusted for potential confounders.
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Results. Individual analyses showed phthalate metabolites: MnBP and MBzP
alongside BPA to be higher among participants with PAD and AS when compared
to the rest of the study population. Adjusted models for PAD confounders showed
association between phthalate metabolites ≥ LOD and participants with PAD and
AS: MnBP (OR: 1.33; 95%: 1.00 – 2.34); MBzP (OR: 1.16; 95% CI: 1.08 – 2.01)
and BPA (OR: 1.22; 95% CI: 1.02 – 5.07). Furthermore after adjusting the model
for gender and PAD confounders; age, race, and PAD confounders; and gender,
age, race, and PAD confounders we demonstrated association between phthalate
metabolites & BPA with PAD participants and AS.
Conclusion. Our findings suggest a relationship between higher environmental
exposure of certain phthalate metabolites & BPA and increased risk of peripheral
arterial disease (PAD) and atherosclerosis (AS).
Key words: ankle – brachial index, bisphenol A, endocrine disrupting chemicals,
NHANES, peripheral arterial disease, phthalates
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Introduction
The US EPA (United States Environmental Protection Agency) outlines
endocrine disrupting chemicals (EDCs) as “agents that interferes with the
synthesis, transport, elimination, binding, or secretion of natural hormones in the
body that are responsible for the maintenance of reproduction, homeostasis,
behavior, and/or development.” (Kavlock et al., 1996). While numerous chemicals
have EDC activity the most studied chemicals today include phthalates and
bisphenol A (BPA). Phthalates consist of a wide variety of products that include
medical tubing, cosmetics, plastics, and coatings. (Gore et al., 2015). Bisphenol A
is used in products such as toys, food packaging, manufacturing, and other
applications. Due to the fact that essentially everyone uses these day-to-day
products, the overall population is continually exposed. (Meeker and Ferguson.
2011). While earlier research has concentrated on the role of phthalates and
bisphenol A (BPA) in cancer, reproductive, and developmental health problems;
existing research has established associations between diabetes, obesity, and
cardiovascular disease (Anway et al. 2005; Lang et al. 2008; Melzer et al. 2010;
Morgan et al., 2016). Although these establishments have been seen throughout
the literature it is warranted to extend that investigation to peripheral arterial
disease in order to further bridge the gap in knowledge
In this study, we examined the independent association between individual
phthalates and bisphenol A (BPA) with diagnosis of peripheral arterial disease and
participants with atherosclerosis with participants in the NHANES (National Health
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and Nutrition Examination Survey) 3-year cycle for phthalates: 1999 – 2004 and 1year cycle 2003-2004 for bisphenol A (BPA). The aim of this study is to assess: 1)
the mean phthalate levels in PAD defined participants and defined with
atherosclerosis compared to non-diagnosed participants; and 2) the mean
bisphenol A (BPA) levels in PAD defined participants and atherosclerosis
compared to non-diagnosed participants, and 3) the association between higher
EDC exposure and increased risk of PAD/AS respectively.
Methods
Study design and population. NHANES survey encompasses stratified
multistage probability sample representative of the civilian non-institutionalized
U.S. population. The study is recognized based on data from NHANES 1999 2004. Selection was based on individuals within households, households, blocks,
counties and included the oversampling of non-Hispanic blacks and Mexican
Americans in order to deliver consistent evaluations of these groups. Participants
provided written informed consent before their participation. Additionally approval
was acquired from the Human Subjects Committee in the U.S. Department of
Health and Human Services. ABI measurements which is a subclinical measure of
atherosclerosis (Criqui et al. 1992; Newman et al. 1993), were acquired for the
subsample of participants ≥ 40 years of age. The current study sample consisted
of participants ≥ 40 years of age among whom endocrine disrupting chemicals was
available. This resulted in participants (461), of whom had PAD and participants
(390) whom were atherosclerosis defined in NHANES 1999 – 2004 and 178 PAD
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defined participants; 94 atherosclerosis participants; and 1850 normal participants
respectively. Subjects who were omitted because of missing covariates were in
general comparable to the NHANES group in terms of sex, age, race/ethnicity, and
education (data not shown). Secondary examination of the nationally collected
data was done using variables of interest, which were only measured concurrently
during the three NHANES cycles from 1999 - 2000, 2001 - 2002, and 2003 - 2004.
NHANES uses a multifaceted sampling design (multistage, probability, cluster and
stratified) for continuous collection and release of 2-year cross-sectional data sets.
Approval for these suitable examinations and laboratory testing were given to
NHANES by the CDC/ATSDR institutional review board of the CDC. The current
study was considered exempt from review by the local institutional review board.
Peripheral Arterial Disease (PAD) diagnosis. The NHANES ABI is regularly
calculated, verified, and released by the National Center for Health Statistics.
Systolic pressure is measured on the right arm (brachial artery) and both ankles
(posterior tibial arteries). If the participant has one of the following: 1) a rash; 2)
open wound on the right arm; 3) dialysis shunt; 4) right-sided radical mastectomy;
or any extra condition that would obstruct with correct measurement or cause
discomfort to the participant, the left arm is utilized for the brachial pressure
measurement. Systolic blood pressure is measured twice at each site for
participants 40-59 years old and once at each site for participants ≥ 60 years old
and older. If a health technician cannot obtain a reading at a site they may attempt
an additional reading at the same site after a short-term resting period. The right
ABPI was obtained by dividing the mean systolic blood pressure in the right ankle
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by the mean blood pressure in the arm. The left ABPI was obtained by dividing the
mean systolic blood pressure in the left ankle by the mean blood pressure in the
arm. The mean blood pressure value for the arm and ankles are computed based
on the first and second reading at each site. As the second reading for all
participants ≥ 60 years old is missing the mean values are in fact the first recorded
blood pressure reading at a site. This may furthermore be correct for participants
40-59 years old who have a missing value for the first or second blood pressure
reading. Individuals are omitted from the exam if they weigh over 400 pounds
(weight limitations of equipment) or have bilateral amputations. Additionally to
some participants who were eligible for the exam (≥ 40 years old) might not have
received the exam due to various reasons including: casts, ulcers, dressings, or
other conditions of the participant interfered with testing; participant could not
understand the test instructions or became ill & the test could not be performed;
there was an equipment failure; participant refused; participant came late or left
early from the MEC & the LED exam could not be performed; and some other
reason. As a result, these eligible individuals will have missing data for the ABPI
variables. Peripheral arterial disease diagnosis was defined as having an ankle
brachial index (ABI) < 0.7. Values 0.9 < ABI < 1.3 were considered normal.
Individuals whom demonstrated 0.7 < ABI < 0.9 was defined as atherosclerosis.
Measurements of phthalates & bisphenol A. Both phthalates and bisphenol A
were calculated in urine by the SPE (solid phase extraction) coupled to reverse
phase HPLC-MS/MS (high performance liquid chromatography-tandem mass
spectrometry). Laboratory methods and quality control were reliable across survey
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years and in which documentation is available online (CDC, 2012). Overall we
investigated 7 phthalate metabolites measured in NHANES years 1999 - 2004:
mono-n-butyl phthalate (MnBP), mono-cyclohexyl phthalate (MCHP), mono-ethyl
phthalate (MEP), mono-2-ethylhexyl phthalate (MEHP), mono-isobutyl phthalate
(MiBP), mono-n-octyl phthalate (MOP), and mono-bezyl phthalate (MBzP). BPA
(bisphenol A) was the only phenol included in this study. In order to adjust for urine
dilution, we divided all phthalate metabolites and BPA by urinary creatinine
concentration and used the resultant corrected creatinine concentrations (mg/g)
for all of our analyses. Urine samples with creatinine that represented levels > 300
mg/dL or < 30 mg/dL were excluded in the analysis because the sample(s) were
over-concentrated for an accurate examination (Sata et al., 1995). Furthermore we
provided a limit of detection (LOD) variable for each phthalate metabolite and BPA
in the datasets. The variable is defined with two values: “1” represents the result
was below the limit of detection and “2” represents the result was equal or above
the limit of detection.
Covariates. We considered a range of confounders based on well-established risk
factors for peripheral arterial disease and review of the literature. The resultant
confounders were self-reported in the questionnaire interviews or taken as
laboratory measurements. The demographic variables of gender (men/women),
race (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic
Black, and other race) and age (≥ 40-59, 60-74, and ≥ 75) were obtained during
the NHANES home interview (CDC, 2012). Others obtained include: smoking, BMI
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(18.5 to < 25, 25 to <30, & ≥ 30), diabetes (yes/no), estradiol levels, sex hormone
binding globulin, testosterone, and education.
Statistical Analysis. Analysis were performed using SAS 9.4 (SAS Institute Inc.;
Cary, NC, USA). Appropriate subsampling weights were calculated according to
the National Center for Health Statistics guidelines to adjust for oversampling of
minority groups (CDC, 2013b). All urinary chemicals and metabolites were log
transformed and creatinine adjusted. PROC SURVEYMEANS was used to
account for the complex sampling design of NHANES and furthermore obtain
means (weighted), 95% confidence intervals, and standard errors of individual
phthalate metabolites and BPA. Age was divided into three groups (≥ 40-59, 60 –
74, and ≥ 75 years old). A two-sided student t-test was measured using PROC
SURVEYREG to test if the mean EDC (phthalates/BPA) levels between
participants who were defined with PAD, AS, and normal participants were
significantly different. Geometric mean (GM) levels and geometric standard errors
(GSE) were reported for peripheral arterial disease status, AS status, age at
interview, and race/ethnicity for all participants with individual phthalate
metabolites & BPA levels. Age was divided into three groups (≥ 40-59 years, 6074 years, and ≥ 75 years) that were selected based on the age distribution of PAD
cases, cases of AS, and normal cases in the population. Race/ethnicity was
divided into five groups (Mexican American, other Hispanic, Non-Hispanic White,
Non-Hispanic Black, and other race).
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Results
Phthalate and Bisphenol A Descriptive Statistics. The study population for
phthalates includes 3,489 men and 3,125 women from NHANES cycles 1999 –
2004 with available data and who are either identified with peripheral arterial
disease (n = 461), atherosclerosis defined (n = 390), or as a normal participant (n
= 5773) as shown in Table 3.1. Bisphenol A population from NHANES 2003 – 2004
includes 868 men and 946 women from NHANES cycle 2003 – 2004 with available
data (Table 3.2). Overall 178 participants are diagnosed with PAD; 94 whom are
at identified with atherosclerosis; and 1850 whom are considered normal
participants. The majority of the participants in the phthalate population was NonHispanic White: 268 (3.72%) for PAD participants; 236 (4.90%) for participants
with AS; and 3,125 (69.64%) normal diagnosed participants. Table 3.3 displays
Cases/Non-Cases, geometric means (GM), and geometric standard error (GSE).
GM of particular phthalate metabolites were significantly higher in participants
diagnosed with PAD and AS when compared to normal diagnosed participants.
Those phthalate metabolites include: MnBP (27.12 & 24.99 vs. 24.16) and MBzP
(13.63 & 12.21 vs. 11.69). Furthermore, BPA also showed significant higher GM
in diagnosis of PAD and AS when compared to normal participants (4.65 & 7.67
vs. 2.73). Table 3.4 illustrates estimated odds ratios (ORs) and 95 % confidence
intervals (CIs) for phthalate metabolites and bisphenol A adjusted for 1) PAD
confounders (diabetes, smoking, and alcohol use); 2) gender and PAD
confounders 3) age, race, BMI, & PAD confounders; and 4) gender, age, race, BMI
and PAD confounders. In the PAD confounders adjusted model phthalate
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metabolites: MnBP (OR: 1.33; 95% CI: 1.00 – 2.34) and MBzP (OR: 1.16; 95% CI:
1.08 – 2.01) showed significant association with PAD and AS when exposure is ≥
LOD. Furthermore bisphenol A also showed significant association with PAD and
AS when exposure is ≥ LOD (OR: 1.22; 95% CI: 1.02 – 5.07). In the gender and
PAD confounders adjusted model phthalate metabolites: MnBP (OR: 1.83; 95%
CI: 1.00 – 2.34); MCHP (OR: 1.54; 95% CI: 1.00 – 2.10), MEP (OR: 1.01; 95% CI:
0.44 -1.09) and MBzP (OR: 1.76; 95% CI: 1.58 – 2.91) showed significant
association with PAD and AS when exposure is ≥ LOD. BPA showed significant
association with PAD and AS when exposure is ≥ LOD (OR: 2.89 95% CI: 1.50 –
10.19). The age, race, BMI, and PAD confounders model demonstrated that
phthalate metabolites: MnBP (OR: 1.33; 0.89 – 2.95); MCHP (OR: 1.39; 95% CI:
1.00 – 1.65); and MiBP (OR: 1.48; 95% CI: 1.12 – 1.87) showed significant
association with PAD and AS when exposure is≥ LOD. In the final model adjusted
for gender, age, race, BMI, and the PAD confounders phthalate metabolites MCHP
(OR: 1.34; 95% CI: 1.22 – 1.59) and MiBP (OR: 1.41; 95% CI: 0.99 – 1.83) showed
significant association with PAD and AS when exposure is ≥ LOD. BPA also
showed significant association (OR: 3.02; 95% CI: 0.14 – 12.15) with PAD and AS
when exposure is ≥ LOD.
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Table 3.1 Descriptive statistics for PAD & selected covariates among participants ≥ 40 years
of age, NHANES 1999 – 2004.
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Estimated percent distribution after applying NHANES sampling weights
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)
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Table 3.2 Descriptive statistics for PAD & selected covariates among participants ≥ 40 years
of age with bisphenol A (BPA) measurements NHANES 2003 - 2004.
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Estimated percent distribution after applying NHANES sampling weights
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Table 3.3. Geometric mean of urinary phthalate metabolites and BPA levels above the LOD
by PAD status among participants ≥ 40 years of age, NHANES 1999 - 2004

Phthlate Metabolites¹
MnBP
MCHP
MEP
MEHP
MiBP
MOP
MBzP
Bisphenol A²
BPA

ABI < 0.7*

Cases/Non-Cases
0.7 < ABI < 0.9*

0.9 < ABI < 1.3*

ABI < 0.7

Geometric Mean³ (ng/g) (GSE)
0.7 < ABI <0.9

0.9 < ABI < 1.3

384
456
175
210
180
384
400

320
250
223
520
869
320
380

5198
5196
5504
5172
4853
5198
5122

27.12 (22.21, 33.10)
0.55 (0.50, 0.60)
127.33 (102.40, 158.34)
3.58 (2.87, 4.45)
1.05 (0.99, 1.11)
1.22 (1.18, 1.27)
13.63 (11.26, 16.50)

24.99 (20.58, 31.12)
0.62 (0.55, 0.70)
120.80 (98.68, 147.86)
2.97 (2.48, 3.55)
1.03 (0.97, 1.09)
1.21 (1.18, 1.25)
12.21 (10.13, 14.71)

24.16 (23.24, 25.12)
0.58 (0.56, 0.60)
136.31 (129.59, 143.38)
3.44 (3.28, 3.62)
1.04 (1.01, 1.07)
1.23 (1.21, 1.24)
11.69 (11.13, 12.28)

142

77

1427

4.65 (3.27 - 6.04)

7.67 (5.75 - 9.59)

2.73 (2.64 - 5.82)

¹ Log transformed and creatinine corrected phthalate metabolites (ng/mg); NHANES 1999 - 2004
² Log transformed and creatinine corrected BPA (ng/mg); NHANES 2003 - 2004
³ Geometric means calculated after applying NHANES sampling weights
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)
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Table 3.4 Estimated ORs (95% CIs) of PAD status by concentration of creatinine adjusted
urinary phthalate metabolites & BPA among participants ≥ 40 years of age, NHANES 1999 –
2004 & 2003 – 2004.
Phthlate Metabolites¹
MnBP
< LOD
≥ LOD
MCHP
< LOD
≥ LOD
MEP
< LOD
≥ LOD
MEHP
< LOD
≥ LOD
MiBP
< LOD
≥ LOD
MOP
< LOD
≥ LOD
MBzP
< LOD
≥ LOD
Bisphenol A²
BPA
< LOD
≥ LOD

ABI < 0.7*

0.7 < ABI < 0.9*

0.9 < ABI < 1.3*

Adjusted OR (95% CI)³

Adjusted OR (95% CI)⁴

294
90

239
81

4032
1166

1
1.33 (1.00 - 2.34)

1
1.83 (1.00 - 2.34)

1
1.33 (0.89 - 2.95)

1
0.96 (0.85 - 1.99)

400
10

341
3

5400
86

1
0.54 (0.25 - 2.10)

1
1.54 (1.00 - 2.10)

1
1.39 (1.00 -1.65)

1
1.34 (1.22 - 1.59)

49
360

44
297

603
4876

1
0.99 (0.44 - 1.05)

1
1.01 (0.44 - 1.09)

1
0.85 (0.55 -1.09)

1
0.98 (0.51 - 1.28)

407
3

339
1

5429
48

1
0.72 (0.40 - 0.93)

1
0.92 (0.40 - 0.93)

1
0.94 (0.92 - 0.95)

1
0.92 (0.93 - 0.96)

410
7

341
13

5457
21

1
0.79 (0.18 - 0.80)

1
0.59 (0.18 - 0.80)

1
1.48 (1.12 - 1.87)

1
1.41 (0.99 - 1.83)

410
10

341
9

5489
34

1
0.95 (0.95 -1.60)

1
0.97 (0.95 - 1.60)

1
0.92 (0.70 - 1.49)

1
0.98 (0.47 - 1.57)

131
277

103
236

1916
3551

1.16 (1.08 - 2.01)

1
1.76 (1.58 - 2.91)

1
0.91 (0.84 - 0.97)

1
1.73 (0.92 - 3.18)

8
141

8
71

118
1315

1
1.22 (1.02 - 5.07)

1
2.89 (1.50 - 10.19)

1
2.17 (1.65 - 7.17)

1
3.02 (0.14 - 12.15)

1

Adjusted OR (95% CI)⁵ Adjusted OR (95% CI)⁶

¹ Log transformed and creatinine corrected phthalate metabolites (ng/mg); NHANES 1999 - 2004
² Log transformed and creatinine corrected BPA (ng/mg); NHANES 2003 - 2004
³ Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use)
⁴ Adjusted for Gender & PAD confounders
⁵ Adjusted for Age, Race, & PAD confounders
⁶ Adjusted for Gender, Age, Race, & PAD confounders
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)

Discussion. In this cross-sectional study of participants aged ≥ 40 years old, we
separately investigated 7 individual phthalate metabolites and BPA in association
with peripheral arterial disease (PAD) and atherosclerosis (AS). In participants with
detectable levels of phthalates and BPA, higher exposures were found in
participants diagnosed with PAD and AS when compared to normal participants
and phthalate metabolites: MnBP and MBzP. Furthermore when ORs and 95% CI
models were adjusted for various models higher exposure phthalate metabolites
& BPA (≥ LOD) showed significant association with participants diagnosed with
PAD and AS [1) PAD confounders model: MnBP and MBzP; 2) gender and PAD
confounders model: MnBP, MCHP, MEP, and MBzP 3) age, race, BMI, and PAD
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confounders model: MnBP, MCHP, and MiBP and 4) gender, age, race, BMI, &
PAD confounders model: MCHP, MiBP, and MBzP].
Previous epidemiological studies showed that phthalate metabolite MMP
was associated with atherosclerotic plaques in an inverted U-shaped manner (low
levels of MMP have an effect) independently of cardiovascular risk factors. Some
phthalates and BPA were also correlated to the echogenicity of the plaques,
suggesting a role for plaque-associated chemicals in atherosclerosis (Lind and
Lind. 2011). Furthermore irregular associations between phthalates and
hyperlipidemia were shown with self-reported diabetes and CVD in Shanghai
adults (Dong et al. 2017). BPA levels were demonstrated to be significantly
associated with PAD before and after adjusting for confounders (Shankar et al.
2012). There is additional evidence that individuals with higher urinary BPA levels
are more inclined to suffer from general or abdominal obesity, hypertension, and
diabetes when compared with individuals having lower urinary concentrations
(Rancière et al. 2015). Common carotid artery intima-media thickness (CIMT)
measured by ultrasonography is a recognized indicator of

subclinical

atherosclerosis and independent predictor of myocardial infarction, coronary
events, and stroke (Bots et al. 1997; Hodis et al. 1998; Su et al. 2006; Chien et al.
2008; Su et al. 2012). It was reported that in a cross-sectional investigation of a
representative population sample of subjects aged 60 - 80 years old showed a
significant association between small changes in IMT and both symptomatic and
asymptomatic peripheral arterial disease (Allan et al. 1997). Lin et al further
determined the relationship between levels of BPA and carotid-media thickness
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(CIMT) and discovered higher serum concentrations of BPA were associated with
increased CIMT in a cross-sectional study of adolescents and young adults (Lin et
al. 2015). Although previous studies and our current study show significant
associations between EDCs (phthalates and BPA) with peripheral arterial disease
further research is warranted to elucidate mechanisms of these associations.
The main strengths of our study include oversampling of minority
populations that make it highly representative and generalizable to the United
States population and availability of biological measurements of environmental
pollutants. Additionally this study is nationally representative and uses stringent
methods to collect available data on confounders. One limitation of this study is
since it is a cross – sectional design with self - reported data, it does not permit for
causal inferences to be concluded. Self – reported data increases the likelihood of
misclassification bias of cases and controls contributing to the possibility of
incorrectly or undiagnosed reported PAD and/or AS cases. Another limitation is
that BPA measurements are more likely to result in misclassification due to
variability.
Conclusion
Based on our analysis of phthalate metabolites from 1999 – 2004 and BPA from
2003 – 2004 higher exposure of particular phthalate metabolites and BPA did
demonstrate association with participants who are diagnosed with PAD alongside
AS. Given earlier and existing research demonstrates exposure to other EDCs
such as polychlorinated biphenyls are associated with cardiovascular disease, it is
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biologically plausible that exposure to phthalates and BPA may contribute to higher
risk of the disease. Our research findings coupled with previous epidemiological
evidence concerning EDCs and peripheral arterial disease warrants the necessity
for prospective future studies.
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CHAPTER V
MANUSCRIPT 4
Genome-wide gene expression profiling of Inhibitor of DNA
binding/Differentiation-3 (ID3) candidate targets in vascular-intimal lesions
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Abstract
Obliterative and proliferative vascular intimal lesions are categorized by
perturbations of cellular constituents & their normal patterning of vessels. The
pathophysiologic pathways that transition to these end-stages are infrequently
distinct. Because they may suggest the normal assembly of vessels during
development, developmental biology, which combines embryologic analyses of
cellular origins, lineage, and cell–cell interactions with genetic studies, holds the
prospect of revealing the role of individual genes in the pathogenesis of vascular
disease. The Inhibitor of DNA binding/Differentiation-3 (ID3), a member of the ID
family of transcriptional regulators, has been shown to play a role in lipoxygenase
(12/15-LO) which is known to produce pro-inflammatory alterations in blood
vessels that lead to the development of atherosclerosis. Furthermore studies have
shown overexpression of ID3 increasing OCT4 and SOX2 expression in
microvascular endothelial cells. Therefore we determined the functional role of ID3
and ID3 candidate target genes in obliterative and proliferative vascular-intimal
lesions. We performed a meta-analysis on published whole genome microarray
datasets comparing transcriptional patterns of blood cells & tissue samples to
controls. Bioinformatics network analysis identified statistically the most
overrepresented processes and signaling pathways. Deciphering the pattern &
role of genes involved with ID3 & ID3 targets in obliterative and proliferative
vascular diseases may provide a new model by which ID3 may contribute to the
growth regulation of these vascular intimal-lesions. Keywords: bioinformatics,
ID3, vascular diseases, vascular-intimal lesions
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Introduction
Although poorly understood, obliterative & proliferative vascular-intimal
lesions are a significant health problem that may lead to blocked blood vessels
and can cause threatening end organ damage such as ischemic stroke, blindness,
right-sided heart failure, or myocardial infarction. Obliterative & proliferative
vascular-intimal lesions manifest in numerous vascular diseases such as
arteriosclerosis, idiopathic pulmonary arterial hypertension, peripheral arterial
disease, and lymphangioleiomyomatosis. The endothelium plays an essential role
in classifications of obliterative and proliferative diseases. A vital foundation of
vascular biology is that the lining of the endothelial is dynamically a changeable
interface. This is locally responsive to multiple types of stimuli that can originate
from the emigrating & circulating cells and/or neighboring tissues and thus can
actively participate in the physiologic variation or vascular dysfunction of a certain
section of the vasculature. The endothelium appears to be best suited to function
in this capacity, given its distinctive anatomic location between tissue & blood and
ability to generate various biological effectors such as cytokines, growth
stimulators & inhibitors, vasoactive peptides, pro- & anti-coagulants, and nitric
oxide. Disruption in the production or interactions of these different mediators
appear to effect various vital functions of the endothelium, specifically its role as a
non-thrombogenic vessel for antithrombotic, growth inhibitory, and antiinflammatory activities; and blood that aids to preserve the integrity of the vascular
wall, when facing injury-related stimuli and various disease risk factors (Fishman
et al. 1998).
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Conceivably the most well-known studied model of activation of vascular
endothelium are the effects of pro-inflammatory cytokines such as tumor necrosis
factor (TNF) and interleukin-1 (IL-1). These have provided a widely used
experimental model, which have been studied at the tissue level (various diseased
human tissues & animal models) and cellular level (receptors, genetic regulatory
events, & signaling pathways) (Fishman et al.1998; Cuthins et al. 2012; Sakurai et
al. 2004). Additionally, the effects of the biochemical dynamisms produced by
pulsatile blood flow including pressures, wall shear stress, & cyclic strains on
endothelial structure and function as been seen as another model of vascular cell
activation. The capability of laminar shear stresses to up-regulate atheroprotective
endothelial genes and significantly influence the functional phenotype of
endothelial cells indicates that this model of activation may be playing a significant
pathophysiologic role. Although the evidence implicates tissue and cellular levels
as an influence on obliterative & proliferative vascular intimal-lesions, the
pathogenesis is far from clarified to date.
At the molecular level, Inhibitor of DNA binding/Differentiation-3 is a
member of the ID family (ID1-ID4) of helix-loop-helix proteins encoded by an
immediate-early gene responsive to mitogenic signals and oxidative stress.
Besides the regulation of cell differentiation, ID proteins are also positive regulators
of cell growth and play a major role in neovascularization. An increasing body of
evidence suggests that ID3 may be involved in disruptions characterized by
abdominal

obesity,

insulin

resistance,

hyperglycemia,

dyslipidemia,

and

hypertension. Interactions across multiple organ systems that contribute to
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disruption presents a challenge to ongoing research attempting to elucidate
biological mechanisms of chronic disease such as vascular. For example, insulin
resistance and systemic low-grade inflammation result from complex interactions
between the vasculature, metabolic tissue, and immune cells. In the vasculature,
ID3 is essential to embryonic vasculogenesis and endothelial cell activation
(Sakurai et al., 2004; Felty & Porther, 2008; Elen et al., 2015). ID3 involvement in
vascular disease has been studied together with the lipoxygenase (12/15-LO),
which is a vital mediator of VSMC growth and its growth-promoting effects were
shown to be mediated by ID3 transcription (Taylor et al., 2015). Increased
expression of 12/15-LO in the vessel wall enhanced ID3-dependent cell
proliferation, fibronectin deposition, and neo-intimal formation (Taylor et al., 2015).
Population established studies have found an SNP (single nucleotide
polymorphisms) rs11574 in the coding region of the human ID3 gene associated
with subclinical atherosclerosis in the Diabetes Heart study (Doran et al., 2010).
Furthermore two cohorts determined the link between the SNP directly with
coronary artery pathology. ID3 has also been shown as a key mechanism of high
fat diet stimulated through visceral adipose VEGFA expression, depot expansion
and micro-vascular blood volume (Cuthins et al., 2012). ID3 is important to obesity
because it has been suggested to stimulate angiogenesis, a major factor of HFD
(high-fat diet)-induced visceral adiposity (Cuthins et al., 2012).
Our research has recently shown that ectopic overexpression of ID3
increased OCT4 and SOX2 expression in endothelial cells as well as resulted in a
population of cells that were positive for the molecular stemness signature CD133+
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VEGFR3+ CD34+ (Das et al., 2015). These endothelial stem cells were
morphologically distinguished into smooth muscle cells and neuron cells. Based
on these findings, ID3 maintains cells in a non-committed state by inhibiting the
repression of pluripotency factors by TCF3. Furthermore we also recently reported
that ID3 overexpression increased endothelial cell neovascularization, resistance
to apoptosis, cell migration, and increased size of endothelial spheroids. In vivo,
we reported that ID3 expression is higher in pulmonary vascular lesions. Our
studies have also shown ID3 protein and oxidative damage highly expressed in
benign and malignant cardiovascular tissues in patients (Das & Felty, 2014). In this
study, we have elucidated the role of ID3 and ID3 candidate target genes in
vascular-intimal lesions with the specific focus on how ID3 may play a critical role
in regulating various genes and signaling pathways that are involved in cell
adhesion, extracellular matrix proteolysis, & cell growth which predisposes the
vessel to vascular dysfunction. A better understanding of how vascular-intimal
lesions depend on ID3 regulation may open up novel approaches for both
prevention & treatment of diseases these intimal-lesions manifest from.
Materials & Methods
Identification of microarray datasets & analysis. Our study was based on
multiple studies carried out and deposited in NCBI Gene Express Omnibus (GEO),
a public functional genomics data repository supporting MIAME-compliant data
submissions in which both sequence-based and array data are accepted. Datasets
were compiled on vascular diseases and respectively divided into blood & tissue
studies. The following tables represents information on data collected & accessible
110

demographics of individual datasets. Note not all datasets are represented in the
tables. Figure 3.1 represents a flow chart of our current study.
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112
GSE78811
GSE12027
GSE53515
GSE48149
GSE60436

GPL20115
GPL96
GPL18096
GPL16221
GPL6884

GEO Accession Number Platform

Vascular Diseases (Tissue Studies)

Infantile hemangioma
Lymphangioleiomyomatosis
Arteriovenous Malformations
Idiopathic pulmonary arterial hypertension
Proliferative Diabetic Retinopathy

GSE40960
GSE18014
GSE13139
GSE6054
GSE36487
GSE20129
GSE12261
GSE20484
GSE9820
GSE33463
GSE22356
GSE43742
GSE34989
GSE5579
GSE27034

GPL570
GPL6104
GPL570
GPL570
GPL96
GPL6104/GPL10558
GPL570
GPL570
GPL6255
GPL6947
GPL570
GPL10558
GPL13607
GPL570
GPL570

GEO Accession Number Platform

Arteriovenous Malformations
Arteriovenous Malformations
Atherosclerosis
Atherosclerosis
Atherosclerosis
Atherosclerosis
Atherosclerosis
Atherosclerosis
Atherosclerosis
Idiopathic pulmonary arterial hypertension
Idiopathic pulmonary arterial hypertension
Infantile hemangioma
Infantile hemangioma
Lymphangioleiomyomatosis
Periperal Arterial Disease

Vascular Diseases (Blood Studies)

22595
13211
22229
18630
25428

3
14
40
36
6

Number of genes in GeneChip Cases

Agilent-067406 Human CBC lncRNA + mRNA microarray V4.0
[HG-U133A] Affymetrix Human Genome U133A Array
Agilent-028004 SurePrint G3 Human GE 8x60K Microarray
Illumina HumanRef-8 v3.0 expression beadchip
Illumina HumanWG-6 v3.0 expression beadchip

Affymetrix Type

3
2
30
10
2
39
6
2
18
30
8
2
29
3
19

Number of genes in GeneChip Cases
21049
18196
21025
21049
13211
18196
21049
21049
18189
37805
21025
31333
34809
21025
21025

Affymetrix Type
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Illumina humanRef-8 v2.0 expression beadchip
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
[HG-U133A] Affymetrix Human Genome U133A Array
Illumina humanRef-8 v2.0 expression beadchip/Illumina HumanHT-12 V4.0 expression beadchip
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Illumina humanRef-8 v2.0 expression beadchip
Illumina HumanHT-12 V3.0 expression beadchip
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Illumina HumanHT-12 V4.0 expression beadchip
Agilent-028004 SurePrint G3 Human GE 8x60K Microarray
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

Citation (Authors & Year)
Young et al., 2012
Wustehube et al., 2010
Mattaliano et al., 2009
Mosig et al., 2008
Minta et al., 2012
Huang et al, 2011
Zaugg et al, 2015
Gleissner et al., 2010
Schirmer et al., 2009
Cheadle et al., 2012
Risbano et al., 2012
Stiles et al., 2013
Harbi et al., 2016
Irigoyen et al., 2007
Masud et al., 2012

Citation (Authors & Year)
Liu et al., 2016
Zhang et al., 2009
Torring et al., 2014
Hsu et al., 2011
Ishikawa et al., 2015

Controls
3
2
24
13
1
6
6
2
13
41
10
2
5
1
18

Controls
3
11
40
9
3

Table 4.1 NCBI GEO datasets represented in study. Table is divided into two cohorts: blood and tissue
samples.

Blood studies

Characteristics

Age, years
Men, %
Ever smoker, %
BMI, kg⋅ m -2
Systolic BP, mm Hg
Diastolic BP, mm Hg
HDL cholesterol, mg/dl
Hypertension, %
Diabetes, %
Lipid-lowering medication, %
Ankle-brachial index
WBC count, µL
Values are expressed as either
'mean ± standard deviation' or
as 'n (%)'

Samples
Cases (n = 19) Controls (n = 18)
69.57 ± 9.18
13 (68%)
17 (89%)
28.53 ± 5.25
139.2 ± 23.27
74.2 ± 11.66
44.12 ± 8.59
17 (89.4%)
5 (26%)
11 (57%)
0.48 ± 0.20
8.03 ± 2.34

66.88 ± 9.44
13 (72%)
12 (66%)
30.6 ± 5.99
132.4 ± 20.1
80.1 ± 12.3
49.7 ± 15
13 (72%)
4 (22%)
12(66%)
1.12 ± 0.07
7.26 ± 1.10

Table 4.2.1 Characteristics of peripheral arterial disease dataset.

Patient ID

Lesions
Age at time of resection
Location & Size
hemcEC-1
8 months
1.8 x 0.8 cm, right eyelid
hemEC-4
3 months
3 x 3, right flank
hemEC-5
4 months
5 mm, lower abdomen
heomaEC-8B
2 years
B - ankle
heomaEC-8C
C - knee
heomaEC-8F
F - right foot
heomaEC-8G
G - inner thigh
10
hemEC-10
2 years
4 cm, forehead
12
hemEC-12
4 months
1.5 cm, left cheek
13
hemEC-13
9 months
3 cm, left upper eyelid
17
hemEC-17A
10 months
A. 3 cm, scalp
hemEC-17B
B. 3.5 x 4 cm, forehead
20
8 months
8 months
2.5 cm, neck
21
9 months
9 months
6.5 x 5.5 cm, scalp
*Endothelial cells from these patients showed a normal (46, XX) karyotype
1
4
5
8

Comments
Normal karyotype*
Multiple hemangiomas
Normal karyotype*, multiple
hemanigoendothelioma lesions of variable size, new lesions still appearing at 2 years

Other hemangiomas on neck and labia

Multiple hemangiomas
Other hemangiomas on right ear and forehead

Table 4.2.2 Characteristics of infantile hemangioma dataset.
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Gender
Age (years)
LDL (mg/dl)
HDL (mg/dl)
Triglycerides (mg/dl)
Lp(a) (mg/dl)
Leukocytes (Gpt/l)
Thrombocytes (Gpt/l)
Values are means ± SD. FH, familial hypercholesterolemia; Gpt, Giga particles; Tpt, Terra particles.

Homozygous FH
Female (n=6)
Male (n=20)
30.2 ± 11.1
413.82 ± 92.33 (***)
60.33 ± 8.09
141.31 ± 39.89
676.67 ± 347.06
7.64 ± 0.95
253.12 ± 22.2

Heterozygous FH
Female (n=5)
Male (n=3)
28.8 ± 7.5
220.64 ± 27.81 (***)
54.17 ± 3.71
233.61 ± 132.80
442.73 ± 420.11
5.45 ± 0.57
277.39 ± 37.51

Controls
Female (n=16)
Male (n=10)
33.8 ± 11.2
107.03 ± 17.78
61.17 ± 6.60
107.63 ± 33.04
187.53 ± 153.59
6.38 ± 0.8
258.12 ± 21.97

Table 4.2.3 Characteristics of atherosclerosis dataset.
Variable
CAC (coronary artery calcification)
n (number of patients)
Gender (male or female)
Age (years)
Body mass index (kg/m2*)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Triglycerides (mg/dl*§)
Fasting glucose (mg/dl)
HOMA insulin resistance
Insulin (uIU/ml)
Current smoker (%)
Lipid-lowering medication use (%)
Antihypertension medication use (%)
*P<0.05 comparing African American with white among women with coronary artery calcification (CAC) < 10
§P <0.05 comparing African American with white among women with CAC > 100

Africian American
CAC < 10
17
female
64.1 ± 7.7
32.0 ± 6.4
119.1 ± 17.3
68.6 ± 7.8
191.8 ± 32.4
113.5 ± 27.7
61.6 13.1
83.7 32.8
91.5 8.0
0.92 0.45
4.4 2.0
23.5
5.8
47

White
CAC < 10
41
female
62.9 ± 6.8
25.5 ± 4.2
114.4 ± 18.7
65.9 ± 11.1
197.5 ± 31.0
110.2 ± 27.5
65.0 15.6
111.3 67.5
89.7 8.5
0.74 0.39
3.6 1.8
37.5
15.3
25.6

Africian American
CAC >100
13
female
68.3 ± 8.5
30.9 ± 7.1
130.6 ± 18.2
71.4 ± 9.5
199.7 29.7
122.6 30.4
61.3 13.5
78.6 29.8
90.6 7.5
1.04 0.55
4.8 2.4
53.8
38.4
53.8

White
CAC > 100
26
female
69.0 ± 6.5
27.4 ± 4.6
130.0 ± 22.6
67.1 ± 8.7
204.0 37.0
119.0 39.1
59.1 12.6
129.2 72.3
91.0 8.7
1.06 0.70
4.9 3.1
48
52
48

Table 4.2.4 Characteristics of atherosclerosis dataset.

Baseline characteristics
Atherosclerotic patients (n=18)
55.8 ± 7.9
8 (44.4)
25.2 ± 3.5
1.90 ± 0.21
14 (77.8)
4 (22.2)
7 (38.9)
15 (83.3)
18 (100)
18 (100)
6 (33.3)
8 (44.4)
8 (44.4)
4 (22.2)
1.0 [1.0; 1.4]
<0.03
5.5 ± 1.7
1.17 ± 0.90
343 [63, 569]
2.20 ± 0.79
1.39 ± 0.46

Age (years)
Male sex-no (%)
Body mass index (BMI)
Body surface area (BSA)
Family history of CAD – no. (%)
Current smoker – no. (%)
Ex smoker – no. (%)
Beta-blockers – no. (%)
Statins – no. (%)
Aspirin – no. (%)
Calcium antagonists – no. (%)
Nitrates – no. (%)
ACE-inhibitors/ARBs – no. (%)
Diuretics – no. (%)
C-reactive protein. – mg/dl
Troponin T – ng/ml
Glucose – mmol/l
Triglycerides – mmol/l
Lipoprotein (a) – mg/dl
LDL-cholesterol – mmol/l
HDL-cholesterol – mmol/l
1) Patients with triple-vessel coronary artery disease and control patients
did not show differences in clinical characteristics except for lipoprotein
2) CAD = coronary artery disease
ARB = Angiotensin receptor blockers
ACE = angiotensin converting enyzme
⁎ Data expressed as median [1. quartile, 3. quartile]

Table 4.2.5 Characteristics of atherosclerosis dataset.

114

Control patients (n=13)
52.2 ± 7.2
5 (38.5)
27.4 ± 3.5
1.97 ± 0.25
6 (46.2)
4 (30.8)
4 (30.8)
10 (76.9)
13 (100)
13 (100)
2 (16.4)
4 (30.8)
7 (53.8)
4 (30.8)
1.1 [1.0; 1.7]
<0.03
5.7 ± 0.6
0.90 ± 0.63
90 [49; 163]
1.87 ± 0.53
0.90 ± 0.63

Tissue Studies
Patient ID
1
2
3
4
5

Age
2 months 15 days
2 months 13 days
1 year
8 months
3 months

Gender
Female
Female
Female
Female
Male

Position
Left axilla
Right posterior neck
Abdomen
Right thoracic wall
Thoracic wall

Previous treatment
NO
Oral propranolol
Sclerotherapy
Sclerotherapy
NO

Pathology
IH
IH
IH
IH
IH

Table 4.2.6 Characteristics of infantile hemangioma dataset.
Family No.
9
9
13
13
15
15
15
24
24
37
38
49
61
65
87
92
93
94
96
8
8
18
18
18
20
42
43
43
46
47
56
57
57
67
67
69
71
82
88
88

Age
49
53
54
30
47
38
40
40
46
51
37
47
49
35
38
44
37
30
46
55
28
43
44
41
47
32
38
36
39
40
44
34
32
24
31
39
44
48
56
50

Sex
M
F
F
F
F
M
F
F
F
M
F
F
F
F
M
M
M
M
M
M
M
M
F
M
M
F
F
F
M
F
F
M
F
F
M
M
F
M
F
M

Phenotype
E,T,P,G,F
E,T,F
E,T,P,G,F
E,T,P,F
E,T,G,F
E,T,P,F
E,T,F
E,T,F
E,T,P,G,F
E,T,P,F
E,T,F
E,T,F
E,T,F
T,P,F
T,P,F
E,T,P
E,T,F
E,T,F
E,T,P,F
E,T,F
E,T,F
E,T,F
E,T,P,F
E,T,F
E,T
E,T,F
E,T,F
T,F
E,T,F
E,T,F
E,T,F
E,T,F
T,F
E,T,F
E,T,F
E,T,F
E,T,F
E,T,F
E,T,G,F
E,T,F

Abbreviations: AVM, arteriovenous malformation; E, epistaxis; T,
Telangiectasia; P, pulmonary AVM; C, cerebral AVM;
G, gastrointestinal telangiectasia/gastrointestinal bleeding; H,
Hepatic AVM; F, family history. M, male; F, female.

Table 4.2.7 Characteristics of arteriovenous malformation dataset.
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Patient ID
1
3
4
5
6
7
8
9
10
11
13
14
15
16
17
18
19
21
22
23
24
25
26
27
28
29
30
32
33
35
36
37
38

Gender (Age)
M 56.8
F 57.8
F 51.3
F 39.3
M 59.0
M 46.3
F 26.5
F 41.8
F 56.4
M 45.3
M 42.5
F 34.6
F 47.7
F 36.8
F 56.7
F 42.3
F 37.0
F 56.2
M 60.0
F 51.7
M 45.1
F 51.8
M 57.5
F 41.6
M 58.2
F 60.1
F 58.8
F 63.8
F 63.5
M 54.2
M 49.0
M 47.2
F 49.0

0
10
10
0
40
0
0
0
60
0
8
0
1
7
0
15
0
55
0
39
0
12
0
5
30
0
0
0
0
0
30
0
30

Smoking

Skin disease

(pack years)

(type)
limited
limited
diffuse
diffuse
n/a
limited
sine
limited
limited
diffuse
diffuse
diffuse
diffuse
limited
limited
limited
diffuse
n/a
diffuse
limited
n/a
diffuse
diffuse
diffuse
diffuse
limited
n/a
limited
limited
n/a
diffuse
diffuse
limited

Autoantibody
Th/To
centromere
n/a
Scl-70
centromere
centromere
U11/U12 RNP
centromere
Th/To
Scl-70
U1 RNP
U11/U12 RNP
Scl-70
Th/To
centromere
Scl-70
n/a
n/a
Scl-70
n/a
n/a
n/a
n/a
U11/U12 RNP
RNA polymerase
Scl-70
n/a
centromere
RNA polymerase
n/a
U11/U12 RNP
n/a
n/a

40
88
34
24
80
76
28
61
64
30
36
28
18
85
74
46
18
41
60
36
26
23
33
42
63
61
39
59
82
40
76
52
26

FVC

FEV-1

(%)

(%)
48
85
43
31
80
80
33
69
34
34
45
33
17
91
74
56
21
29
70
44
28
25
46
44
77
70
50
70
95
47
67
58
32

DLCO (%)

FVC% / DLCO
%

(mmHg)
34
38
22
31
24
40
39
34
29
23
31
32
n/a
83
30
14
n/a
25
36
20
30
n/a
26
31
16
20
14
n/a
25
n/a
n/a
20
19

1.18
2.32
1.55
1.55
3.33
1.9
0.71
1.79
2.2
1.3
1.16
0.88
n/a
1.02
2.47
3.28
n/a
1.64
1.67
1.8
0.87
n/a
1.27
1.35
3.93
3.05
2.79
n/a
3.28
n/a
n/a
2.6
1.37

Table 4.2.8 Characteristics of idiopathic pulmonary arterial hypertension dataset.

116

Mean PAP
18
51
30
22
47
48
13
62
42
23
50
n/a
14
60
52
24
26
43
48
22
23
20
24
15
38
23
19
44
31
38
43
35
21

Figure 4.1 Flow chart summarizing the steps in this study.
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Computational identification of ID3 and ID3 candidate target genes.
Respectively each dataset has a different number of genes signifying the genome
(~13,000 – 35,000). To compare the data, the identification of commonly
expressed genes across all studies in both blood and tissue was first established.
A total number of 3665 genes were commonly represented in each study. In order
to remove systematic variation in the microarray experiments which affects the
measured gene expression levels, raw data was discretized using the function: (IF
(Sample>Average+0.5*Standard

Deviation,

2,

IF

(Sample>Average-

0.5*Standard*, 1, 0))). Expression levels were signified as 0 (under/lowexpression), 1 (normal expression), & 2 (overexpression). To classify ID3
candidate target genes, a pearson correlation test was conducted. This is a
measure of linear correlation between two variables: X & Y and is represented by
a value between

-1 and 1, where -1 is a total negative correlation, 0 is no

correlation, & 1 is a total positive correlation. Additionally the interquartile range
(IQR), which is a measure of variability, based on dividing a set of data in quartiles
(Q1 - 25th percentile, Q2- 50th percentile, Q3 – 75th percentile, and Q4 – 100th
percentile) was calculated. Genes that were measured between Q3 (75 th
percentile) & Q4 (100th percentile) were identified as best correlated with ID3.
Additionally an independent t-test, which compares the means of two independent
groups in order to determine whether there is statistical evidence that the
associated population means are significantly different was used to test statistical
differences between means of two groups (disease and control). Our common
gene list (3665) was used during our t-test and significance value was considered
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at p≤ 0.05 and IQR was determined. Genes measured in the Q1 (25 th percentile)
was represented as significant. In order to generate the conclusive list of ID3
candidate targets, genes that were mutually expressed in Q3 and Q4 of the
Pearson correlation analysis and Q1 of the t-test were included as candidate
targets. This method was done separately for whole blood and tissue studies.
Furthermore the top 10 most significant ID3 targets in both blood and tissue
samples were also identified.
Bayesian analysis & network. Due to the development of biomedical data in
biology & medicine with vast number of variables, Bayesian networks have been
successfully used in developing effective algorithms that scale up to datasets
connecting numbers of variables in learning high quality predictive models from
genomic data (Yoo et al. 2002; Yoo and Cooper, 2004). A Bayesian network is a
directed acyclic graph in which each node represents a variable and each arc
represents probabilistic influence. In Bayesian Networks, each arc is interpreted
as a direct influence between a parent node (variable) and a child node, relative to
the other nodes in the network. Structure of Bayesian network with respect to a
decomposable score such as BIC, BDe, or AIC becomes infeasible as the number
of variables increases. A much simpler algorithm for finding the globally optimal
Bayesian network structure without any structural limitations is used with n<33
which is also known as Bene. The approach is broken down into five logical steps:
Step 1. Compute the local scores for all n2n − 1 different (variable, variable set) –
pairs; Step 2. Using the local scores, find the best parents for all n2n−1 (variable,
parent candidate set)-pairs; Step 3. Find the best sink for all 2n variable sets; and
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Step 4. Using the results from Step 3, find a best ordering of the variables. Step 5.
Find a best network using results computed in Steps 2 and 4 (Silander &
Myllymak).
Genie. Genie Modular is a graphical user interface to SMILE (Structural Modeling,
Interface, & Learning Engine) is a fully platform independent library of C++ classes
applying decision-theoretic models & graphical probabilistic, such as Bayesian
networks, influence diagrams, and structural equation models. A graph
demonstrates much about the structure of a probabilistic domain but not much
about its numerical properties. These are encoded in conditional probability
distribution matrices (equivalent to the factors in the factorized form), called
conditional probability tables (CPTs) that are associated with the nodes. There will
always be nodes in the network with no predecessors. These nodes are
categorized by their prior marginal probability distribution. Any probability in the
joint probability distribution can be determined from these explicitly represented
prior and conditional probabilities.
Gene Ontology & Pathway Analysis. To understand the functions of the gene
list we applied two gene ontology tools: Princeton University Lewis-Sigler Institute
for Integrative Genomics Gene Ontology (GO) Tools (http://go.princeton.edu/), &
STRING database version 10 (http://string-db.org/). All tools provide a
knowledgebase of functional annotation tools for investigators to understand
functional meaning (biological, molecular) behind various sizes of gene lists.
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Comparative Toxicogenomic Database (CTD) Analysis. CTD is a publicly
available database that aims to advance understanding about how environmental
exposures affect human health (Davis et al. 2016). The database provides curated
information about chemical–gene/protein interactions, chemical–disease and
gene–disease relationships. The data are integrated with functional and pathway
data to support in development of hypotheses about the mechanisms essential
environmentally predisposed diseases. To understand the association between
endocrine disrupting chemicals (PCBs and BPA) & ID3/ID3 target genes, CTD was
used to investigate the association between PCB/BPA associated genes & ID3/ID3
target genes identified in both blood and tissue respectively. Furthermore
overlapping blood-tissue ID3 target genes and their association with both PCBs
and BPA was also examined. Results were summarized in venn diagrams and final
lists was provided for each.
Results
Gene expression of ID3 & ID3 candidate targets in blood & tissue studies.
We identified ID3 & ID3 candidate target genes in all blood studies and tissue
studies. Table 4.3 and 4.5 shows a listing of ID3 and ID3 candidate target genes.
In blood, 217-candidate target genes were identified and in tissue 134-candidate
target genes were identified. Top 10 most significant ID3 target genes were
identified in blood & tissue studies summarized in tables 4.4 & 4.6. Top 10 most
significant ID3 targets in blood includes: COL1A2, COL6A1, CYP2C18, DIRAS3,
DLG2, DZIP1, GCLM, GDF11, GRP, and KNG1. The top 10 most significant ID3
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targets in tissue includes: ACLY, ACP1, ARPC4, ATP5D, CAMK1, CDKN2B,
COPE, CYC1, EIF4EBP2, and MCRS1.
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Table 4.3 ID3 and ID3 candidate target genes identified in blood studies.
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Gene Symbol
COL1A2
COL6A1
CYP2C18
DIRAS3
DLG2
DZIP1
GCLM
GDF11
GRP
KNG1

Entrez Gene Title
collagen type I alpha 2 chain (COL1A2)
collagen type VI alpha 1 chain (COL6A1)
cytochrome P450 family 2 subfamily C member 18 (CYP2C18)
DIRAS family GTPase 3 (DIRAS3)
discs large MAGUK scaffold protein 2 (DLG2)
DAZ interacting zinc finger protein 1 (DZIP1)
glutamate-cysteine ligase modifier subunit (GCLM)
growth differentiation factor 11 (GDF11)
gastrin releasing peptide (GRP)
kininogen 1 (KNG1)

Table 4.4 Top 10 most significant ID3 candidate target genes in blood.
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Table 4.5 ID3 and ID3 candidate target genes in tissue studies.

Gene Symbol
ACLY
ACP1
ARPC4
ATP5D
CAMK1
CDKN2B
COPE
CYC1
EIF4EBP2
MCRS1

Entrez Gene Title
ATP citrate lyase (ACLY)
acid phosphatase 1, soluble (ACP1)
actin related protein 2/3 complex subunit 4 (ARPC4)
ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit (ATP5D)
calcium/calmodulin dependent protein kinase I (CAMK1)
cyclin dependent kinase inhibitor 2B (CDKN2B)
coatomer protein complex subunit epsilon (COPE)
cytochrome c1 (CYC1)
eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2)
microspherule protein 1 (MCRS1)

Table 4.6 Top 10 most significant ID3 candidate target genes in tissue.

Gene expression in blood versus tissue studies. Overlapping ID3 & ID3
candidate target genes were identified between blood & tissue samples. Genes
include: ABCB6, ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, ID3,
MCM4, and NDUFA7 as shown in Table 4.7 & Figure 4.3 Furthermore we
demonstrated the results in both Bene and Genie models (Figure 4.4 & 4.5.1 –
4.5.4) illustrating a fully connected structure and probability distribution of gene
expression.
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Gene Symbol
ABCB6
ACP1
BYSL
CAD
CDH15
DCBLD2
DHRS3
DNMT1
ID3
MCM4
NDUFA7

Entrez Gene Title
ATP binding cassette subfamily B member 6 (Langereis blood group) (ABCB6)
acid phosphatase 1, soluble (ACP1)
bystin like (BYSL)
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD)
cadherin 15 (CDH15)
discoidin, CUB and LCCL domain containing 2 (DCBLD2)
dehydrogenase/reductase 3 (DHRS3)
DNA methyltransferase 1 (DNMT1)
inhibitor of DNA binding 3, HLH protein (ID3)
minichromosome maintenance complex component 4 (MCM4)
NADH: ubiquinone oxidoreductase subunit A7 (NDUFA7)

Table 4.7 ID3 and common candidate target genes between blood and tissue studies.

Figure 4.2 Venn diagram illustration summarizes ID3 & ID3 candidate target genes. Left circle represent
genes in blood studies (134), right circle represent genes in tissue studies (217), & the middle intersection of
the two circles represent the shared genes between both blood & tissue studies (11).
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Figure 4.3 Representation of ID3 and overlapping ID3-candidate target genes in both blood and
tissue samples. Bene, a method for finding the globally optimal Bayesian network produced a fully
connected structure.
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Figure 4.4.1 Best fit model based on Genie Modeler with overlapping ID3 & ID3-candidate target
genes.
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Figure 4.4.2 Representation of ID3 & ID3-candidate targets in vascular state. Left panel represents
model in disease state and right panel represents model in non-disease state.
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Figure 4.4.3 Representation of ID3 & ID3-candidate targets in location of vascular disease. Left panel
represents model in blood & right panel represents model in tissue.
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Figure 4.4.4 Representation of models based on expression of ID3. Left panel summarizes ID3 lowexpression, middle panel represents ID3 normal-expression, & the right panel summarizes ID3-high
expression.

Gene expression of ID3 & ID3 candidate target genes in specific vascular
diseases in blood & tissue. Our investigation indicated the expression of ID3 &
ID3 candidate target genes within each vascular disease. Figure 4.6.1 illustrates
the diverse number of candidate targets and overlapping genes between each
disease in blood studies. Number of candidate targets genes (n) include:
atherosclerosis (357); arteriovenous malformation (36); peripheral arterial disease
(190); proliferative diabetic retinopathy (403); infantile hemangioma (84); idiopathic
pulmonary arterial hypertension (75); & Lymphangioleiomyomatosis (363).The
analysis also identified ID3 & ID3 candidate target genes within each vascular
disease in tissue studies. Figure 4.6.2 illustrates the diverse number of candidate
targets and overlapping genes between each disease. Number of candidate
targets genes (n) include: arteriovenous malformation (277); proliferative diabetic
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retinopathy (403); infantile hemangioma (98); idiopathic pulmonary arterial
hypertension (973); & Lymphangioleiomyomatosis (231).

Figure 4.5.1 Venn diagram illustration summarizes ID3 & ID3 candidate target genes in vascular
diseases in blood studies. Each shape represents a different disease that includes blood samples. Diseases
include: IH (Infantile Hemangioma), PAD (peripheral arterial disease), AVM (arteriovenous malformation),
LAM (Lymphangioleiomyomatosis), IPAH (idiopathic pulmonary arterial hypertension), & AS (atherosclerosis).
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Figure 4.5.2 Venn diagram summarizes ID3 & ID3 candidate target genes in specific diseases in tissue
studies. Each ovular shape represents a vascular disease. Diseases in tissue studies include: IH (Infantile
Hemangioma), AVM (arteriovenous malformation), LAM (Lymphangioleiomyomatosis), PDR (Proliferative
Diabetic Retinopathy), & IPAH (Idiopathic pulmonary arterial hypertension).
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ID3 & ID3 gene-associated biological processes
ID3 and ID3 candidate target genes in blood. In order to understand the roles
of these genes in functional processes a gene ontology approach was used via the
Princeton University Lewis-Sigler Institute for Integrative Genomics Gene
Ontology (GO) Tool to demonstrate the processes in which ID3 & ID3 candidate
target genes in blood were represented. The genes were demonstrated in 122
biological processes and are represented in Table 4.8.
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Table 4.8 Demonstration of biological processes that ID3 & ID3 target genes are involved with in blood.
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ID3 and ID3 candidate target genes in tissue. In order to understand the roles
of these genes in functional processes gene ontology methodology was used to
demonstrate the processes in which ID3 & ID3 candidate target genes in tissue
were overrepresented. Candidate target genes in tissue were overrepresented in
89 biological processes.
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Table 4.9 Biological processes that ID3 & ID3 candidate target genes in tissue.

ID3 & ID3 gene-associated signaling pathways
ID3 and ID3 candidate target genes in blood. In order to understand the
potential relationships among the genes in the most over-represented processes
STRING, a database of predicted & identified protein-protein interactions was used
to show direct (physical) and indirect (functional) associations. ID3 & ID3 candidate
target genes in blood (134) was matched to the database and generated network
maps for the genes involved in over-represented processes. We show that ID3 and
ID3 candidate target genes in blood are involved in 5 pathways (Arrhythmogenic
right ventricular-cardiomyopathy, Neuro-active ligand-receptor interaction, focal
adhesion, ECM-receptor interaction, & hypertrophic cardiomyopathy as shown in
Table 4.10 Interestingly two of the pathways represented ID3 as matching proteins.
Focal adhesion pathway includes proteins: ACTN1, COL1A2, COL3A1, COL6A1,
CTNNB1, IBSP, ID3, ITGA8, and MYL2. ECM-receptor interaction includes
proteins: COL1A2, COL3A1, COL6A1, IBSP, ID3, and ITGA8. Figure 4.7.1 and
4.7.2 demonstrate both networks. Furthermore we also represented the biological
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processes these genes (134) are signified as seen in Table 4.11. Overall 119
biological processes are over-represented via ID3 & ID3 candidate genes in blood.

Table 4.10 Demonstrated pathways of ID3 and ID3 candidate targets genes in blood.
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Figure 4.6.1 Network demonstrated from STRING database of ID3-involved pathway in Extra Cellular
Matrix Receptor (ECM) interaction. Genes (6) highlighted in red are involved in the pathway: COL1A2,
COL3A1, COL6A1, IBSP, ID3, and ITGAB
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Figure 4.6.2 Network demonstrated from STRING database of ID3-involved pathway in focal
adhesion. Genes (9) highlighted in red are involved in the pathway: ACTN1, COL6A1, COL6A2, COL3A1,
CTNNB1, IBSP, ID3, ITGAB, and MYL2.
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Table 4.11 Biological processes represented through STRING database of ID3 & ID3-candidate targets
proteins in blood. Table represents 119 biological processes.

ID3 and ID3 candidate target genes in tissue. Furthermore we also used
STRING to investigate the potential relationships among ID3 & ID3 candidate
target genes in tissue (217). These genes demonstrate to be involved in 20
pathways as shown in Table 4.12. Additionally two of the pathways represented
have a role in vascular diseases. Oxidative phosphorylation pathway included
proteins: ATP5D, ATP5H, ATP6V0B, ATP6V0D1, ATP6V1B2, COX5A, COX7C,
COX8A, CYC1, ID3, NDUFA1, NDUFA7, NDUFS4, NDUFV1, and NDUFV2. Cell
cycle pathway includes: ANAPC10, ATM, CDKN2B, E2F5, MCM3, and MCM4.
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Figures 4.8.1 and 4.8.2 represent both pathways. We also show the biological
processes in which these genes (217) are over-represented in. A total of 116
processes are shown in Table 4.13.

Table 4.12 Demonstrated pathways of ID3 & ID3 candidate target proteins in tissue.
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Figure 4.7.1 Network demonstrated from STRING database of ID3 candidate targets involved in the
oxidative phosphorylation pathway. Proteins involved in the pathway: ATP5D, ATP5H, ATP6V0B,
ATP6V0D1, ATP6V1B2, COX5A, COX7C, COX8A, CYC1, NDUFA1, NDUFA7, NDUFS4, NDUFV1, and
NDUFV2.

Figure 4.7.2 Network demonstrated from STRING database of ID3 candidate targets involved in the cell
cycle pathway. Proteins include: ANAPC10, ATM, CDKN2B, E2F5, MCM3, and MCM4.
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Table 4.13 Biological processes of ID3 and ID3 candidate target genes in tissue. Gene ontology (GO)
shown via STRING database demonstrate 116 biological processes.
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ID3 & ID3 candidate target genes & EDC-associated genes. Comparative
Toxicogenomic Database examination yielded various results. When comparing
ID3 candidate target genes in blood (134) with PCB associated genes (648) results
demonstrated 12 genes which include: AEBP1, APOH, CHEK1, DNMT1, DTYMK,
FKBP4, GFRA1, HIST1H4C, ID3, IL6, LIFR, and MTTP (Figure 4.9.1 & Table
4.15.1). Furthermore, when comparing ID3 candidate target genes in tissue (217)
with PCB associated genes (648) results showed 13 genes including: ACOX1,
ACTR2, ALDOC, CDK2AP2, CSF3R, CTSZ, DNMT1, GPI, HSP90AB1, ID3, ILF2,
ITGB5, LY96 (Figure 4.9.2 & Table 4.15.2). Additionally, we also investigated two
specific PCB congeners (PCB153 and PCB180) and examined their associated
genes with ID3/ID3 candidate target genes. ID3 candidate target genes in blood
(134) and PCB153-associated genes (2016) resulted in 19 genes including: CCL7,
CTNNB1, DCX, DLG2, DTYMK, DUSP14, FNBP1, GRIN2B, HMGB3, HNF4G,
HS3ST1, HTR4, IFIH1, IGFBP2, IL6, LIFR, MCM4, MMP11, and NDUFA7 (Figure
4.9.4 & Table 4.15.4). ID3 candidate target genes in tissue (217) and PCB153associated genes (2016) resulted in 24 genes: ABCA1, AOX1, APOD, ASGR2,
ATM, BAX, COG7, EEF2, ELF4, GOT1, GPC5, GPX1, HIST1H1B, HMGCR,
HTATIP2, IDH2, IL2RA, MAPK1, MCM3, MCM4, MGST3, MTM1, MVK, NDUFA7
(Figure 4.9.5 & Table 4.15.5). When comparing ID3 candidate target genes in
blood (134) with PCB180-assciated genes (1876) results yielded 20 genes
including: ACTN1, ARID5B, CACNG3, CCL7, CHEK1, DCX, DLG2, DUSP14,
FBLN5, FNBP1, GRIN2B, HDAC4, HMGB3, HNF4G, HS3ST1, HTR4, IFIH1, IL6,
MCM4, and NDUFA7 (Figure 4.9.7 & Table 4.15.7). ID3 candidate target genes in
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tissue (217) vs. PCB180-associated gens (1876) resulted in 18 genes: APOD,
ATM, BAX, COG7, ELF4, GPC5, HIBCH, HSP90AB1, HTR2A, IL2RA, LGALS1,
LGALS3BP, MAPK1, MCM3, MCM4, MGST3, MTM1, and NDUFA7 (Figure 4.9.8
& Table 4.15.8). Lastly we also demonstrated BPA-associated genes (19169) with
ID3 candidate targets in both blood and tissue respectively. These results indicated
126 genes in blood and 202 genes in tissue further demonstrated in Figures 4.10.1
& 4.10.2 and Tables 4.16.1 & 4.16.2.

Figure 4.8.1 Venn diagram illustrating ID3 candidate target genes in blood with PCBs. ID3 candidate
target genes (134), PCB associated genes (648), and overlapping genes (12).

Associated ID3 Target Genes in blood with PCBs
AEBP1
APOH
CHEK1
DNMT1
DTYMK
FKBP4
GFRA1
HIST1H4C
ID3
IL6
LIFR
MTTP
Table 4.14.1 ID3 candidate target genes in blood associated with polychlorinated biphenyls
(PCBs).
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Figure 4.8.2 Venn diagram illustrating ID3 candidate target genes in tissue with PCBs. ID3 candidate
target genes (217), PCB associated genes (648), and overlapping genes (13)

Associated ID3 Target Genes in tissue with PCBs
ACOX1
ACTR2
ALDOC
CDK2AP2
CSF3R
CTSZ
DNMT1
GPI
HSP90AB1
ID3
ILF2
ITGB5
LY96
Table 4.14.2 ID3 candidate target genes in tissue associated with polychlorinated biphenyls (PCBs).
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Figure 4.8.3 Venn diagram summarizing overlapping ID3 candidate target genes in blood-tissue with
PCBs. ID3 candidate target genes (11), PCB associated genes (648), and overlapping genes (2)

Overlapping ID3 Candidate Target Genes
Genes in blood-tissue with PCBs
DNMT1
ID3
Table 4.14.3 Overlapping ID3 candidate target genes in blood-tissue associated with polychlorinated
biphenyls (PCBs).

Figure 4.8.4 Venn diagram summarizing ID3 candidate target genes in blood with PCB153. ID3
candidate target genes (134), PCB153 associated genes (2016), and overlapping genes (19)
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Associated ID3 Candidate Target Genes in blood with PCB153
CCL7
CTNNB1
DCX
DLG2
DTYMK
DUSP14
FNBP1
GRIN2B
HMGB3
HNF4G
HS3ST1
HTR4
IFIH1
IGFBP2
IL6
LIFR
MCM4
MMP11
NDUFA7
Figure 4.14.4 ID3 candidate target genes in blood associated with polychlorinated biphenyl 153
(PCB153).

Figure 4.8.5 Venn diagram summarizing ID3 candidate target genes in tissue with PCB153. ID3
candidate target genes (217), PCB153 associated genes (2016), and overlapping genes (24).

174

Associated ID3 Candidate Target Genes in tissue with PCB153
ABCA1
AOX1
APOD
ASGR2
ATM
BAX
COG7
EEF2
ELF4
GOT1
GPC5
GPX1
HIST1H1B
HMGCR
HTATIP2
IDH2
IL2RA
MAPK1
MCM3
MCM4
MGST3
MTM1
MVK
NDUFA7
Figure 4.14.5 ID3 target genes in tissue associated with polychlorinated biphenyl 153 (PCB153).

Figure 4.8.6 Venn diagram summarizing ID3 candidate target genes in blood-tissue. ID3 candidate target
genes (11), PCB153 associated genes (2016), and overlapping genes (2).
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Overlapping ID3 Candidate Target Genes
in blood-tissue with PCB153
MCM4
NDUFA7
Figure 4.14.6 ID3 target genes in blood-tissue associated with polychlorinated biphenyl 153
(PCB153).

Figure 4.8.7 Venn diagram summarizing ID3 target genes in blood with PCB180. ID3 candidate target
genes (134), PCB180 associated genes (1876), and overlapping genes (20).

Associated ID3 Candidate Target Genes in blood with PCB180
ACTN1
ARID5B
CACNG3
CCL7
CHEK1
DCX
DLG2
DUSP14
FBLN5
FNBP1
GRIN2B
HDAC4
HMGB3
HNF4G
HS3ST1
HTR4
IFIH1
IL6
MCM4
NDUFA7

Figure 4.14.7 ID3 candidate target genes in blood associated with polychlorinated biphenyl 180
(PCB180).
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Figure 4.8.8 Venn diagram summarizing ID3 candidate target genes in tissue with PCB180. ID3
candidate target genes (217), PCB180 associated genes (1876), and overlapping genes (18).

Associated ID3 Candidate Target Genes in tissue with PCB180
APOD
ATM
BAX
COG7
ELF4
GPC5
HIBCH
HSP90AB1
HTR2A
IL2RA
LGALS1
LGALS3BP
MAPK1
MCM3
MCM4
MGST3
MTM1
NDUFA7

Figure 4.14.8 ID3 candidate target genes in tissue associated with polychlorinated biphenyl 180
(PCB180).

Figure 4.8.9 Venn diagram summarizing overlapping ID3 candidate target genes in blood-tissue with
PCB180. ID3 candidate target genes (11), PCB180 associated genes (1876), and overlapping genes (2).
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Overlapping ID3 Candidate Target
Genes in blood-tissue with PCB180
MCM4
NDUFA7

Table 4.14.9 ID3 candidate target genes in blood-tissue associated with polychlorinated biphenyl 180
(PCB180).

Figure 4.9.1. Venn diagram summarizing ID3 candidate target genes in blood with BPA. ID3 candidate
target genes (134), Bisphenol A associated genes (19169), and overlapping genes (126).

178

ABCA4
ABCB6
ACIN1
ACP1
ACTA2
ACTN1
ADAMTS3
AEBP1
AGTR2
ANKRD26
ANPEP
APAF1
APOF
APOH
ARID5B
ARSA
ASB4
ASNS
ATP7B
AVPR2
BCAM
BCL2L2
BYSL
C10ORF10
CACNB4
CACNG3
CAD
CALR
CCL7
CCT8
CDH15
CDH16
CDH17
CDH2
CDH6
CFDP1
CFTR
CH25H
CHEK1
CKM
CNKSR2
COL17A1

COL1A2
COL3A1
COL6A1
COPB2
CREBBP
CRYAA
CTGF
CTH
CTNNB1
CTSF
CYP26A1
CYP4F11
CYR61
DAAM1
DAB2
DCX
DHRS3
DHRS7
DIRAS3
DLG2
DNAJC7
DNMT1
DOCK9
DRD1
DTYMK
DUSP14
DYRK3
DZIP1
EEF1E1
ETS1
FBLN2
FBLN5
FBP2
FKBP4
FNBP1
FUT9
GABRA2
GAL
GAS8
GCLM
GDF11
GFRA1

GLRA1
GPR135
GPR37L1
GRIA2
GRIK5
GRIN2B
GRP
HDAC4
HDDC2
HMGB3
HMGCS2
HNF4G
HOXD3
HS3ST1
HSPB2
HTR4
IBSP
ID3
IFIH1
IGFBP2
IL13RA2
IL6
INHBB
ITGA8
KCNH2
KCNJ4
KCNK1
KIF1A
KNG1
LGR5
LIFR
LMO3
MAN1A2
MCM4
MLLT10
MMP11
MPP3
MPP6
MTTP
MYL2
NDP
NDUFA7

Table 4.15.1 ID3 candidate target genes in blood associated with BPA.

Figure 4.9.2. Venn diagram summarizing ID3 candidate target genes in tissue with BPA. ID3 candidate
target genes (217), Bisphenol A associated genes (19169), and overlapping genes (202)
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ABCA1
ABCB6
ACLY
ACOX1
ACP1
ACTR1A
ACTR2
ADRM1
AGGF1
AHCTF1
AK2
ALDH3B1
ALDOC
ALPL
ANAPC10
AOX1
AP2S1
API5
APOD
APRT
ARCN1
ARF4
ARF5
ARFGEF2
ARID3A
ARL1
ARPC1A
ARPC4
ASGR2
ASPHD1
ATF6
ATM
ATOX1
ATP5D
ATP5H
ATP6V0B
ATP6V0D1
ATP6V1B2
AXIN1
BAX

BAX
BCAP31
BCAR3
BCAT2
BCL7B
BNIP3
BYSL
C4BPB
CAD
CAMK1
CASK
CCDC6
CCNI
CD2BP2
CD99
CDH15
CDK2AP2
CDK5
CDKN2B
CEBPG
CHMP2A
CLN3
CLPP
CLTB
COG7
COMMD4
COPE
COPS3
COPS7A
COX5A
COX7C
COX8A
CSF3R
CSPG5
CTNNBIP1
CTSZ
CYB561D2
CYC1
CYHR1
DAP

DCTN2
DCTN5
DDB1
DDN
DDO
DEGS1
DHCR7
DHRS3
DHX16
DHX8
DNAJB6
DNAJC8
DNASE2
DNMT1
DPM2
DYRK4
E2F5
EEF2
EIF2B1
EIF4EBP2
EIF4G1
EIF5A
ELAC2
ENO1
EPHA1
EPRS
ERAL1
ERCC2
FAM20B
FAM50A
FLAD1
FLOT2
FRAT2
FXR2
FZD2
G3BP2
GABRD
GALK2
GATA2
GBF1

GLB1
GOLGA3
GOSR2
GOT1
GPAA1
GPC5
GPD1L
GPI
GPR39
GPR4
GPX1
GRIN2D
H1F0
HAGH
HCLS1
HERC4
HESX1
HIBCH
HIST1H1B
HIST1H1D
HMGCR
HSP90AB1
HTATIP2
HTR2A
ICA1
ID3
IDH2
IDH3B
IDH3G
IFNGR2
IGFBP5
IL2RA
ILF2
IMP4
ITGAM
ITGB5
IVD
KIFAP3
KPNA4
KRT19

LASP1
LGALS1
LGALS3BP
LMAN1
LMNA
LRRC42
LSM3
LY96
M6PR
MAPK1
MAPK13
MAPKAPK3
MAPRE1
MCM3
MCM4
MCRS1
MFGE8
MFSD5
MGAT1
MGST3
MIF
MPDU1
MPI
MPPE1
MR1
MRPL12
MRPS12
MSN
MTHFS
MTM1
MYBPC2
MYO7A
NAGLU
NAGPA
NCK1
NCSTN
NDST1
NDUFA1
NDUFA7
NDUFS4

NDUFV1
NDUFV2
NEDD8

Table 4.15.2 ID3 candidate target genes in tissue associated with BPA.

Discussion
To our knowledge this is a novelty study approach investigating ID3 and ID3
candidate target genes in vascular-intimal lesions. Our analysis intergrading both
statistical & bioinformatics methods attempts to identify ID3 and ID3 candidate
target genes alongside key gene networks that differentiate vascular disease
subjects from non-disease subjects. We have used these approaches to elucidate
a core set of genes in both blood & tissue that represent ID3 and potential targets.
Interestingly 11 of these genes are mutually expressed in the two locations of
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vascular diseases: blood & tissue. These genes whose involvement in various
biological processes such as extracellular matrix, focal adhesion, & cell growth
may help explain how ID3 signaling drives vascular dysfunction in the
pathogenesis of these vascular diseases, in which vascular-intimal lesions
manifest from. All mutually represented ID3 candidate target genes in both blood
& tissue demonstrate known roles in vascular diseases forming a tight cluster that
is largely centered on the regulation of these biological processes.
The identification of ID3 & ID3 candidate target genes helped truncate our
vast quantity of mutually expressed genes (3665) across all the data. In our
analysis we identified ID3 and ID3 candidate target genes in blood (134) and tissue
(217) studies. In blood, 5 pathways were overrepresented by these genes.
Interestingly, 2 pathways contribute to vascular perturbation in the lesion:
extracellular matrix-receptor interaction & focal adhesion. The extracellular matrix
(ECM); which is a dynamic composite of various proteins that form structures
connecting cells, provides an architectural framework within the network. Blood
vessels are inflated by blood pressure and thus require ECM mechanisms with
enough tensile strength and elasticity to resist rupture (Ponticos & Smith. 2014).
Furthermore focal adhesion, a type of adhesive contact between the cell and
extracellular matrix is essential for proliferation, cell migrations, and embryonic
development (Eleniste & Bruzzaniti. 2012). Together both regulate & control
cellular function through biochemical and mechanical signaling. Cells respond to
the ECM by alternating their environment which becomes dysregulated in vascular
diseases such as atherosclerosis, restenosis, and hypertension (Ponticos & Smith.
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2013). Both components are important for maintaining vascular integrity and
prevention of unfavorable vascular remodeling (Raines. 2000). Overrepresented
genes in both pathways include COL1A2, COL3A1, COL6A1, IBSP, ID3, & ITGA8.
Type I collagens COL1A1 and COL1A2 are part of the fibullar a-cellular component
of basement membranes and connective tissue (Yurchenco, 2011). Most recently
it was shown that the expression of pro-inflammatory genes such as TNF-α and
MCP-1 was significantly up-regulated as well as the expression of the proremodeling genes collagen type I, fibronectin and the metalloproteinase MMP-2
and TIMP-1 (Zelko et al., 2016). Interestingly ID3 snp rs11574 was demonstrated
to up-regulate MMP3 & down-regulate COL6A3 leading to the stimulation of
atherogensis, which includes biological processes such as apoptosis, cell
movement, cellular proliferation, immune trafficking, & adhesion (Doran et al.,
2010). Integrin binding sialoprotein protein (IBSP) is a major structural protein of
the bone matrix. The expression of IBSP also significantly increased on collagen
type I (7 fold), vitrovectin (5 fold), and laminin during a study where the role of ECM
proteins in regulating the proliferation and osteogenic differentiation of bone
marrow derived human mesenchymal stem cells (hMSCs) was examined
(Matthews et al., 2012). In tissue, 20 pathways were overrepresented by ID3
candidate target genes. Two pathways were identified as a contributing factor to
vascular dysfunction: oxidative phosphorylation & cell cycle pathway. Oxidative
phosphorylation, which is the metabolic pathway in which cells use enzymes to
oxidize nutrients is essential in the pathogenesis of vascular disease.
Overproduction of reactive oxygen species (ROS) under various pathophysiologic
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conditions can trigger certain pathways that may lead to vascular inflammation
causing vessel & plaque rupture (Madamanchi et al. 2005; Gao et al. 2008).
Vascular smooth muscle cell proliferation is a key component in the healing
process of vascular dysfunction. This process is facilitated by multiple growth
factors and cytokines which share a common pathway in inducing cell proliferation:
the cell cycle (Braun-Dullaeus et al. 1998; Charron et al. 2006). Key molecular
events in atherogenesis such as phospholipids, endothelial cell activation,
oxidative modification of lipoproteins, and macrophage activation/infiltration are
facilitated by vascular oxidative stress and inhibited by endothelial nitric oxide
(Förstermann et al., 2017). Furthermore angiogenesis in the 3D collagen gel was
demonstrated recently to be regulated by the JAK/STAT3 pathway which involves
alterations in vessel diameter, vessel length, and sprout number. The essential
mechanism was that the JAK/STAT3 signaling pathway regulated angiogenesis by
perturbations in numbers of angiogenesis-associated growth factors and by direct
regulation of cell cycle (Xue et al., 2016). Furthermore the top 10 most significant
ID3 candidate target genes in both blood and tissue were demonstrated. In blood
these genes include: COL1A2, COL6A1, CYP2C18, DIRAS3, DLG2, DZIP1,
GCLM, GDF11, GRP, and KNG1. In tissue these genes include: ACLY, ACP1,
ARPC4, ATP5D, CAMK1, CDKN2B, COPE, CYC1, EIF4EBP2, and MCRS1.
Additionally, genes including: ABCB6, ACP1, BYSL, CAD, CDH15,
DCBLD2, DHRS3, DNMT1, ID3, MCM4, & NDUFA7 are represented both in blood
& tissue data. In order to initially establish if these genes had an interaction within
their network, a globally optimal Bayesian network structure without any structural
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limitations (Silander & Myllymak) provided us with a fully connected structure. In
order to further validate the model, the mutually common genes were implemented
into a Bayesian network that allowed us to determine the probability distribution of
gene expression (low, normal, & high), location of disease (tissue and blood), and
vascular state (disease and no disease). Represented by our initial model it was
predicted that ID3 was predominately expressed as high (high: 79%, normal: 4%,
& low: 17%). Also the vascular state was in close proximity of one another (disease
state: 56%, control state: 44%). We demonstrated in the model when ID3 was
expressed at various levels at 100% (high, normal, & low). Interestingly when ID3
is highly expressed the genes in the model also became highly expressed
predominantly occurring in blood with an evenly distributed vascular state
(disease: 51%, control state: 49%). When ID3 expression is normal, the network
is modeled more in tissue and the vascular state is principally geared toward
vascular disease (disease: 65%, control: 35%). Low expression of ID3 represents
activity principally in tissue toward vascular disease (disease: 66%, control: 34%).
These changes in the model may elucidate to ID3 regulation that exists in this
network. Furthermore we extended our analysis of ID3 candidate target genes in
both

blood

&

tissue

and

investigated

which

genes

are

additionally

estrogenic/endocrine disrupting chemical associated. Results demonstrated that
gene DNMT1 is associated with ID3 candidate genes in both blood & tissue and
PCBs; and genes MCM4 & NDUFA7 are associated with ID3 candidate target
genes in both blood & tissue and PCB153 & PCB180.
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Interestingly each of these genes have been known to be involved in various
vascular diseases through the literature. ABCB6 has been shown to have a new
role in preventing atherosclerosis growth by inhibiting platelet production,
reactivity, and chemokine (C-C motif) ligand-5 deposition in atherosclerotic lesions
(Murphy et al., 2014). ACP1 is identified to be associated with atherosclerosis and
autoimmune diseases in Caucasians. It was shown that rs79716074 genotype of
GA polymorphism in ACP1 is associated with decreased risk of coronary arterial
disease in Chinese northeast population especially in females (Li et al., 2015).
CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and
dihydroorotase) has been demonstrated as an unacknowledged mechanism that
regulates NOTCH/VEGF signaling during angiogenesis (Caxam et al., 2015).
DCBLD2 which is also known as ESDN has been established as a potential
diagnostic and therapeutic target for graft atherosclerosis, which still remains a
cause of progressive, chronic failure in cardiac allograft (Sadeghi et al., 2007).
MCM4, part of a family of pre-replication complexes show that MCM2, MCM4, and
MCM7 mRNA levels are increased in VSMCs during G1 phase, as indicated by
increased Cyclin D1 levels (Guo et al., 2013). Furthermore this family of proteins
is mutually modified by ID3 influence (MCM2, MCM3 and MCM10), such that
genes down-regulated in PMEL-1 RAG1−/−ID3−/− T cells were induced by
overexpression of ID3 (Ji et al., 2011). Also, DNMT1, a differentially expressed
gene that is associated with VSMC-associated diseases which is regulated by 17
miRNAs, where these miRNAs are possible targets for developing anti-R based
miRNA therapy, was recently established (Chen et al., 2017). DHRS3, was
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recently reported to be associated with rheumatoid arthritis (RA), a complex and
prevalent complex inflammatory disease primarily affecting the joint (Wang et al.,
2017). The vascular disease in RA encompasses a large spectrum ranging from
rheumatoid vasculitis to atherosclerotic lesions (Tanasescua et al., 2009).
NDUFA7, a subunit of the complex-I in the mitochondrial respiratory chain was
also demonstrated to be associated with rheumatoid arthritis (RA). Association of
NDUFA7 and RA suggest reactive oxygen species (ROS) in the pathogenesis of
the disease (Mitsunaga et al., 2015). Additionally we have previously shown that
ID3 is an important determinant of ROS-induced proliferation of estrogen exposed
endothelial cells & the overall results suggest ID3 may serve as a beneficial target
for estrogen-dependent vascular-proliferative diseases (Felty & Porther, 2008).
We also demonstrated ID3 overexpressing cells which supported the formation of
a 3-D microvascular lesion co-cultured with smooth muscle cells (Das JK et al.,
2015) and overexpression of ID3 increased neovascularization, cell migration, and
spheroid growth of human cerebral microvascular endothelial cells, hCMEC/D3
(Das & Felty, 2015). We postulate that ID3 does have an essential role in regulation
of these genes that take part in perturbations of vascular-intimal lesions.
Conclusion
In summary, our analysis strongly indicates that ID3 does have a molecular
mechanism that affect changes in extracellular matrix, cell adhesion, & cell growth
which predisposes the blood vessel to vascular dysfunction. Common genes
identified in blood and tissue samples show a strong suggestion for their several
roles in vascular diseases. Therapeutic interventions which aim to target these
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particular processes may indicate great effectiveness in the treatment and
prevention of vascular disease.
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CHAPTER VI
OVERALL CONCLUSIONS
The main objective of the findings in this dissertation was to assess the role
of Inhibitor of DNA-binding/differentiaon-3 (ID3) in vascular diseases with respect
to its regulation of vascular-intimal lesion formation and explanation of how ID3
predisposes the vessel to vascular dysfunction & endocrine disrupting pollutants.
Our approach to bridging gaps between ID3, endocrine disrupting chemicals &
vascular disease warrants unique work.
The initial goal addressed in manuscript 1 was utilized as a literature review
to highlight the current understanding of how ID3 may contribute to multifaceted
chronic diseases via metabolic perturbations such as cancer, neurological
disorders, vascular, autoimmune, and bone diseases. Furthermore the existing
literature suggests chronic exposure to endocrine disrupting chemicals (EDCs)
within the human body are connected with metabolic disorders, and how the
influence of these chemicals affect ID3. Also ID3 has the ability to inhibit or
stimulate gene expression resultant in cellular hyper-proliferation or stemness
markers. Additionally ID3 has been shown to be in involved in metabolic syndrome
(MetS) and EDCs mainly focusing on the three conceivable etiological factors such
as insulin resistance, obesity and adipose tissue disruption, and a group of
independent factors. We also address ID3 and its involvement in molecular
mechanisms & signaling pathways that lead to these various disease outcomes.
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The second aim addressed in manuscript 2 explored the association of
exposure to an endocrine disrupting chemical (PCBs) and participants diagnosed
with peripheral arterial disease as well as participants defined with atherosclerosis.
We analyzed a population 40 years and older with available PCB data from 1999
– 2004. Exposure assessment was based on lipid adjusted concentrations of 6
individual PCB congeners (074, 099, 118, 138, 153, and 180), the sum of dioxinlike PCBs (074+118), and the sum of non-dioxin-like PCBs (099+138+153+180) in
conjunction with examination data obtained from NHANES. We calculated GMs
(geometric means) to compare concentrations of PCBs in participants with PAD
definition, atherosclerosis, and normal participants. GMs of the 6 individual PCB
congeners were established to be higher among participants with PAD diagnosis
as well as atherosclerosis when compared to the rest of the study population. The
overall GM levels of PCBs increased significantly in PAD participants as age group
progressed except PCB099, which demonstrated a non-consistent trend (10.04
ng/g vs. 8.82 ng/g vs. 18.99 ng/g). Furthermore consistent trends were shown in
the first and second age group (≥ 40 – 59) & (60 – 74) years old respectively,
however in the final age group ≥ 75 only 2 PCB congeners showed higher
concentration levels in the diseased status compared to the normal and 4
congeners (099, 138, 153, and 180) shown to have higher PCB GMs in normal
participants. We also demonstrated adjusted models for PAD confounders; gender
and PAD confounders; age, race, BMI, and PAD confounders; and gender, age,
race, BMI, and PAD confounders. All models showed significant association with
individual PCB congeners and increased risk of PAD when LOD ≥ 50.

192

Furthermore, adjusted models for both dioxin-like and non-dioxin-like PCBs also
demonstrated significant association with higher exposure and increased risk of
PAD.
We further extended the second aim in manuscript 3 by exploring the
association between additional types of endocrine disrupting chemicals
(phthalates, BPA) with PAD. GM levels demonstrated higher levels of phthalate
metabolites: MnBP and MBzP in participants diagnosed with PAD and AS when
compared to the rest of the population. Furthermore GM levels of BPA was shown
to be higher in participants diagnosed with PAD and AS when compared to normal
participants. Adjusted models for PAD confounders; gender and PAD
confounders; age, race, BMI and PAD confounders; and gender, age, race, BMI,
and PAD confounders demonstrated significant association with PAD and higher
exposure of phthalate metabolites (≥ LOD) as well as BPA (≥ LOD). PAD
confounder adjusted models showed significant association with phthalate
metabolites: MnBP (OR: 1.33; 95% CI: 1.00 – 2.34) and MBzP (OR: 1.16; 95% CI:
1.08 – 5.07). Additionally PAD confounder adjusted model also demonstrated
significant association with BPA (OR: 1.22; 95% CI: 1.02 – 5.07). Adjusted model
for gender and PAD confounders showed significant association with phthalate
metabolites: MnBP (OR: 1.83; 95% CI: 1.00 – 2.34), MCHP (OR: 1.54 95% CI:
1.00 – 2.10), MEP (OR: 1.01; 95% CI: 0.44 – 1.09), and MBzP (OR: 1.76; 95% CI:
1.58 -2.91) as well as BPA (OR: 2.89; 1.50 – 10.19). Age, race, BMI, and PAD
confounders adjusted model demonstrated significant association with phthalate
metabolites: MnBP (OR: 1.33; 95% CI: 0.89 - 2.95), MCHP (OR: 1.39; 95% CI:
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1.00 -1.65), MiBP (OR: 1.48; 95% CI: 1.12 – 1.87) alongside BPA (OR: 2.17; 95%
CI: 1.65 – 7.15). The final model with gender, age, race, BMI, and the PAD
confounders demonstrate MCHP (OR: 1.34; 95% CI: 1.22 – 1.59), MiBP (OR: 1.41;
95% CI: 0.99 – 1.83), MBzP (OR: 1.73; 95% CI: 0.92 – 3.18) alongside BPA (OR:
3.02; 95% CI: 0.14 – 12.15) showed significant association with higher exposure.
The aim addressed in manuscript 4 investigated the role of ID3 and ID3
candidate target genes in vascular diseases in respect to elucidating the specific
focus of how ID3 plays a role in vascular-intimal lesion formation. ID3 has been
previously shown to be important to the embryonic vasculogenesis and endothelial
cell activation. Additionally it has been shown in various vascular disease
mechanisms such as neo-intimal formation, VSMC growth, visceral adipose
VEGFA expression, & increased endothelial cell neovascularization. We compiled
microarray expression data using NCBI GEO on vascular diseases. Using
computational analysis such as pearson correlation & independent t-test we
identified ID3 candidate targets in blood and tissue respectively. We identified 217candidate target genes in blood and 134-candidate target genes in tissue. Gene
ontology methodology further supported us to explore the role of the identified ID3
candidate target genes in blood and tissue samples (217 and 134 respectively).
Overlapping genes in both blood and tissue were furthermore identified and
include: ABCB6, ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, ID3,
MCM4, and NDUFA7. Utilizing Bayesian network structure without any structural
limitations provided us with a fully connected structure validating an interactive
model. Furthermore we implemented those same genes using Genie to allow us
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to determine probability distribution of gene expression within the network. Our
initial model predicted ID3 to be predominately expressed high (79%) with the
vascular state of the disease being in close proximity of one another (disease state:
56%, control state: 44%). Interestingly these mutually represented genes in both
blood and tissue have been demonstrated in various vascular diseases throughout
the literature such as atherosclerosis and vascular pathology of rheumatoid
arthritis.
In conclusion, the major findings from the research conducted in this
dissertation indicate a number of results. We investigated the role of endocrine
disrupting chemicals (PCBs, phthalates, and BPA) and their association with
vascular disease (PAD). Our findings show higher PCB, specific phthalate
metabolites, and BPA concentrations in participants diagnosed with PAD as well
as those with atherosclerosis when compared to the normal population.
Furthermore, adjusted models demonstrated significant association with higher
exposure to these endocrine disrupting chemicals and increased risk of PAD. ID3
may play a role in regulating certain genes in vascular diseases that take part in
different biological processes that are significant drivers in the growth of vascularintimal lesions such as cell adhesion, extracellular matrix, & cell growth. These
genes include: ABCB6, ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1,
ID3, MCM4, and NDUFA7. Overall, the exposure to EDCs particularly to vascular
disease may contribute to the underlying understanding of how the mechanism of
ID3 regulates certain genes that are essential components of the growth of
vascular-intimal lesions.
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Limitations
There were a number of limitations to our study. For our NHANES study
since it was a cross sectional design it does not allow for casual interpretations
due to self-reported data. Self – reported data increases the likelihood of
misclassification bias of cases and controls contributing to the risk of incorrectly or
undiagnosed reported PAD and/or AS cases. Furthermore, missing data also limits
the overall finding of our study. Additionally, observed associations could be
potentially confounded due to lack of information. For our GEO study not all
dataset characteristics were represented which could lead to bias with various
variables.
Future Studies
Although our findings should be viewed upon with thoughtfulness, they
indicate that research involving the complex combination of environmental &
molecular determinants should warrant further consideration. Additional research
needs to be completed in order to account for the vast intricacy of how these types
of determinants can change the development of not only vascular diseases but
chronic diseases such as cancer and neurological disorders. The combined effects
of EDCs and their influence on the molecular mechanisms that affect disease
outcomes should be evaluated at a more complete perspective. Widespread
exposure to EDCs and overall concern for growth in vascular disease risk,
especially with sensitive molecular & genetic mechanisms permits a strong need
for further research.
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